{"type":"Disease","keywords":[],"medgen_id":"C2748918","id":"9152","name":"Otopalatodigital spectrum disorder","alternate_symbols":[],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0018233\"}","{\"db\":\"Orphanet\",\"id\":\"364541\"}"],"alternate_names":[],"attribute_content":[]}
{"type":"Disease","keywords":[],"medgen_id":"C1835829","id":"1834","name":"Immunodeficiency due to defect in mapbp-interacting protein","alternate_symbols":[],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0012559\"}","{\"db\":\"OMIM\",\"id\":\"610798\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"90023\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Immunodeficiency+due+to+defect+in+mapbp-interacting+protein/8644\",\"ref_field\":\"name\"}"],"alternate_names":[],"attribute_content":[]}
{"type":"Disease","keywords":[],"medgen_id":"C3554129","id":"17484","name":"Combined oxidative phosphorylation deficiency 13","alternate_symbols":[],"symbol":"COXPD13","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0013977\"}","{\"db\":\"OMIM\",\"id\":\"614932\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"319514\"}","{\"db\":\"OMIM\",\"id\":\"614932\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"alternate_names":[],"attribute_content":[]}
{"type":"Disease","keywords":[],"medgen_id":"C0175709","id":"14948","name":"Centronuclear myopathy","alternate_symbols":[],"symbol":"CNM","mode_of_inheritance":"All","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0018947\"}","{\"db\":\"Orphanet\",\"id\":\"595\"}","{\"db\":\"SNOMED CT\",\"id\":\"82077006\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Myotubular myopathy\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000016534\",\"ref_field\":\"mode_of_inheritance\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0018947\",\"ref_field\":\"name\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000016534\",\"ref_field\":\"symbol\"}"],"alternate_names":["Centronuclear myopathy, congenital","Myotubular myopathy"],"attribute_content":[]}
{"type":"Disease","keywords":[],"medgen_id":"C0917804","id":"4617","name":"Cerebral arteriovenous malformation","alternate_symbols":[],"symbol":"BAVM","gard_id":"3020","xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0002408\",\"type\":\"primary\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0007154\"}","{\"db\":\"OMIM\",\"id\":\"108010\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"46724\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0007154\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Arteriovenous malformations of the brain\"}","{\"db\":\"OMIM\",\"id\":\"108010\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CEREBRAL ARTERIOVENOUS MALFORMATIONS\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0002408\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Cerebral AV malformation\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"3020\",\"ref_field\":\"gard_id\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Intracranial+arteriovenous+malformation/3852\",\"ref_field\":\"name\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0002408\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"234142008\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"108010\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"alternate_names":["Arteriovenous malformations of the brain","CEREBRAL ARTERIOVENOUS MALFORMATIONS","Cerebral AV malformation"],"attribute_content":[]}
{"type":"Disease","keywords":[],"medgen_id":"C2676285","id":"507","name":"Bone fragility with contractures, arterial rupture, and deafness","alternate_symbols":[],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0012892\"}","{\"db\":\"OMIM\",\"id\":\"612394\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"300284\"}","{\"db\":\"OMIM\",\"id\":\"612394\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"LH3 DEFICIENCY\"}","{\"db\":\"OMIM\",\"id\":\"603066.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"LYSYL HYDROXYLASE 3 DEFICIENCY\"}","{\"db\":\"OMIM\",\"id\":\"603066.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"LYSYL HYDROXYLASE 3 DEFICIENCY\"}","{\"db\":\"OMIM\",\"id\":\"612394\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"LYSYL HYDROXYLASE 3 DEFICIENCY\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Bone+fragility+with+contractures%2C+arterial+rupture%2C+and+deafness/7852\",\"ref_field\":\"name\"}"],"alternate_names":["LH3 DEFICIENCY","LYSYL HYDROXYLASE 3 DEFICIENCY"],"attribute_content":[]}
{"type":"Disease","keywords":[],"medgen_id":"C3150649","id":"6641","name":"Autoimmune disease, syndromic multisystem","alternate_symbols":[],"symbol":"ADMFD","gard_id":"10775","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0013245\"}","{\"db\":\"OMIM\",\"id\":\"613385\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"228426\"}","{\"db\":\"OMIM\",\"id\":\"606409.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"AUTOIMMUNE DISEASE, MULTISYSTEM, WITH FACIAL DYSMORPHISM\"}","{\"db\":\"OMIM\",\"id\":\"613385\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"AUTOIMMUNE DISEASE, MULTISYSTEM, WITH FACIAL DYSMORPHISM\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"10775\",\"ref_field\":\"gard_id\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Autoimmune+disease%2C+syndromic+multisystem/7775\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"613385\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"alternate_names":["AUTOIMMUNE DISEASE, MULTISYSTEM, WITH FACIAL DYSMORPHISM"],"attribute_content":[]}
{"type":"Disease","keywords":[],"medgen_id":"C1291329","id":"3911","name":"Deficiency of transaldolase","alternate_symbols":[],"symbol":"TALDOD","gard_id":"10445","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0011624\"}","{\"db\":\"OMIM\",\"id\":\"606003\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"101028\"}","{\"db\":\"OMIM\",\"id\":\"606003\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"EYAID SYNDROME\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"10445\",\"ref_field\":\"gard_id\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Transaldolase+deficiency/7161\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"124252008\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"606003\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"alternate_names":["EYAID SYNDROME"],"attribute_content":[]}
{"type":"Disease","keywords":[],"medgen_id":"C3809877","id":"18442","name":"Schaaf-Yang syndrome","alternate_symbols":[],"symbol":"SHFYNG","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0014243\"}","{\"db\":\"OMIM\",\"id\":\"615547\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"398069\"}","{\"db\":\"OMIM\",\"id\":\"615547\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CHITAYAT-HALL SYNDROME\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0014243\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Prader-Willi syndrome due to point mutation\"}","{\"db\":\"OMIM\",\"id\":\"615547\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"alternate_names":["CHITAYAT-HALL SYNDROME","Prader-Willi syndrome due to point mutation"],"attribute_content":[]}
{"type":"Disease","keywords":[],"medgen_id":"C2676767","id":"749","name":"CD59-mediated hemolytic anemia with or without immune-mediated polyneuropathy","alternate_symbols":[],"symbol":"HACD59","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0012858\"}","{\"db\":\"OMIM\",\"id\":\"612300\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"169464\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Cd59+deficiency/7929\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Cd59 deficiency\"}","{\"db\":\"OMIM\",\"id\":\"107271.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HEMOLYTIC ANEMIA, CD59-MEDIATED\"}","{\"db\":\"OMIM\",\"id\":\"612300\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"alternate_names":["Cd59 deficiency","HEMOLYTIC ANEMIA, CD59-MEDIATED"],"attribute_content":[]}
{"type":"Disease","keywords":[],"medgen_id":"C3554593","id":"17702","name":"Retinal dystrophy, iris coloboma, and comedogenic acne syndrome","alternate_symbols":[],"symbol":"RDCCAS","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0014060\"}","{\"db\":\"OMIM\",\"id\":\"615147\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"352718\"}","{\"db\":\"OMIM\",\"id\":\"615147\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"alternate_names":[],"attribute_content":[]}
{"type":"Disease","keywords":[],"medgen_id":"C4015624","id":"32737","name":"Myopathy, vacuolar, with casq1 aggregates","alternate_symbols":[],"symbol":"VMCQA","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0014546\"}","{\"db\":\"OMIM\",\"id\":\"616231\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"88635\"}","{\"db\":\"OMIM\",\"id\":\"616231\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"alternate_names":[],"attribute_content":[]}
{"type":"Finding","keywords":[],"medgen_id":"C1852150","id":"26191","name":"Adermatoglyphia","alternate_symbols":[],"ghr_links":"adermatoglyphia","symbol":"ADERM","gard_id":"12550","xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0007455\",\"type\":\"primary\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0007619\"}","{\"db\":\"OMIM\",\"id\":\"136000\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"289465\"}","{\"db\":\"OMIM\",\"id\":\"136000\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"FINGERPRINTS, ABSENCE OF\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"12550\",\"ref_field\":\"gard_id\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"adermatoglyphia\",\"ref_field\":\"ghr_links\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Adermatoglyphia/7635\",\"ref_field\":\"name\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0007455\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"136000\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"alternate_names":["FINGERPRINTS, ABSENCE OF"],"attribute_content":[]}
{"type":"Disease","keywords":[],"medgen_id":"C1853139","id":"5681","alternate_symbols":[],"symbol":"OPA5","gard_id":"10201","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0012543\"}","{\"db\":\"OMIM\",\"id\":\"610708\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"98673\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Optic+atrophy+5/5383\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Optic atrophy 5\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"10201\",\"ref_field\":\"gard_id\"}","{\"db\":\"OMIM\",\"id\":\"610708\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"alternate_names":["Optic atrophy 5"],"attribute_content":[]}
{"type":"Disease","keywords":[],"medgen_id":"C1829703","id":"8237","name":"Carnitine palmitoyltransferase 1A deficiency","alternate_symbols":[],"gard_id":"1120","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0009705\"}","{\"db\":\"Orphanet\",\"id\":\"156\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0009705\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Carnitine palmitoyl transferase 1A deficiency\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"1120\",\"ref_field\":\"gard_id\"}"],"alternate_names":["CPT1A deficiency","Carnitine palmitoyl transferase 1 deficiency","Carnitine palmitoyl transferase 1A deficiency","Hepatic CPT1","Hepatic carnitine palmitoyltransferase 1 deficiency","L-CPT 1 deficiency"],"attribute_content":[]}
{"type":"Disease","keywords":[],"medgen_id":"C0011854","id":"1089","name":"Diabetes mellitus type 1","alternate_symbols":[],"symbol":"IDDM","xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0100651\",\"type\":\"primary\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0005147\"}","{\"db\":\"OMIM\",\"id\":\"222100\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"181371\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0100651\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Insulin-dependent diabetes mellitus\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0100651\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Juvenile diabetes mellitus\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0100651\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Type I diabetes\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0100651\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Type I diabetes mellitus\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Diabetes+mellitus+type+1/8214\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"46635009\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"222100\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"alternate_names":["Insulin-dependent diabetes mellitus","Juvenile diabetes mellitus","Type I diabetes","Type I diabetes mellitus"],"attribute_content":[]}
{"type":"Disease","keywords":[],"medgen_id":"C3277900","id":"411","name":"Anonychia","alternate_symbols":[],"symbol":"NDNC4","xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001798\",\"type\":\"primary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0007593\",\"type\":\"secondary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0008384\",\"type\":\"secondary\"}","{\"db\":\"OMIM\",\"id\":\"206800\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"79143\"}","{\"db\":\"Orphanet\",\"id\":\"94150\"}","{\"db\":\"OMIM\",\"id\":\"206800\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"ANONYCHIA TOTALIS\"}","{\"db\":\"OMIM\",\"id\":\"206800\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"ANONYCHIA/HYPONYCHIA CONGENITA\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001798\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Absent nails\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001798\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Aplastic nails\"}","{\"db\":\"OMIM\",\"id\":\"206800\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"NAIL DISORDER, NONSYNDROMIC CONGENITAL, 4\"}","{\"db\":\"OMIM\",\"id\":\"610573.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"NAIL DISORDER, NONSYNDROMIC CONGENITAL, 4\"}","{\"db\":\"OMIM\",\"id\":\"610573.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"NAIL DISORDER, NONSYNDROMIC CONGENITAL, 4\"}","{\"db\":\"OMIM\",\"id\":\"610573.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"NAIL DISORDER, NONSYNDROMIC CONGENITAL, 4\"}","{\"db\":\"OMIM\",\"id\":\"610573.0004\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"NAIL DISORDER, NONSYNDROMIC CONGENITAL, 4\"}","{\"db\":\"OMIM\",\"id\":\"610573.0005\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"NAIL DISORDER, NONSYNDROMIC CONGENITAL, 4\"}","{\"db\":\"OMIM\",\"id\":\"610573.0006\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"NAIL DISORDER, NONSYNDROMIC CONGENITAL, 4\"}","{\"db\":\"OMIM\",\"id\":\"610573.0007\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"NAIL DISORDER, NONSYNDROMIC CONGENITAL, 4\"}","{\"db\":\"OMIM\",\"id\":\"610573.0008\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"NAIL DISORDER, NONSYNDROMIC CONGENITAL, 4\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Anonychia+Congenita/488\",\"ref_field\":\"name\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001798\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"10048\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"23610003\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"206800\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"alternate_names":["ANONYCHIA TOTALIS","ANONYCHIA/HYPONYCHIA CONGENITA","Absent nails","Aplastic nails","NAIL DISORDER, NONSYNDROMIC CONGENITAL, 4"],"attribute_content":[]}
{"type":"Disease","keywords":[],"medgen_id":"C4015146","id":"32194","name":"Retinal dystrophy with inner retinal dysfunction and ganglion cell abnormalities","alternate_symbols":[],"symbol":"RDGCA","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0014483\"}","{\"db\":\"OMIM\",\"id\":\"616079\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"397758\"}","{\"db\":\"OMIM\",\"id\":\"616079\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"alternate_names":[],"attribute_content":[]}
{"type":"Disease","keywords":[],"medgen_id":"C4225258","id":"34421","name":"Epilepsy, progressive myoclonic, 10","alternate_symbols":[],"symbol":"EPM10","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0014717\"}","{\"db\":\"OMIM\",\"id\":\"616640\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"324290\"}","{\"db\":\"OMIM\",\"id\":\"616640\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"alternate_names":[],"attribute_content":[]}
{"type":"Disease","keywords":[],"medgen_id":"C4014617","id":"21261","name":"Immunodeficiency 24","alternate_symbols":[],"symbol":"IMD24","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0014391\"}","{\"db\":\"OMIM\",\"id\":\"615897\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"420573\"}","{\"db\":\"OMIM\",\"id\":\"615897\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"alternate_names":[],"attribute_content":[]}
{"type":"Disease","keywords":[],"medgen_id":"C0685889","id":"3827","name":"Asplenia, isolated congenital","alternate_symbols":[],"symbol":"ICAS","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0010066\"}","{\"db\":\"OMIM\",\"id\":\"271400\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"101351\"}","{\"db\":\"OMIM\",\"id\":\"271400\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"ASPLENIA, FAMILIAL\"}","{\"db\":\"OMIM\",\"id\":\"271400\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HYPOSPLENIA, ISOLATED CONGENITAL\"}","{\"db\":\"OMIM\",\"id\":\"271400\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"alternate_names":["ASPLENIA, FAMILIAL","HYPOSPLENIA, ISOLATED CONGENITAL"],"attribute_content":[]}
{"type":"Disease","keywords":[],"medgen_id":"C3809526","id":"18309","name":"Combined oxidative phosphorylation deficiency 17","alternate_symbols":[],"symbol":"COXPD17","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0014190\"}","{\"db\":\"OMIM\",\"id\":\"615440\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"369913\"}","{\"db\":\"OMIM\",\"id\":\"615440\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"alternate_names":[],"attribute_content":[]}
{"type":"Disease","keywords":[],"medgen_id":"C4014291","id":"18726","name":"Oocyte maturation defect 1","alternate_symbols":[],"symbol":"OOMD1","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0014342\"}","{\"db\":\"OMIM\",\"id\":\"615774\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"404466\"}","{\"db\":\"OMIM\",\"id\":\"615774\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"alternate_names":[],"attribute_content":[]}
{"type":"Disease","keywords":[],"medgen_id":"C3554657","id":"17753","name":"Lissencephaly 5","alternate_symbols":[],"symbol":"LIS5","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0014077\"}","{\"db\":\"OMIM\",\"id\":\"615191\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"352682\"}","{\"db\":\"OMIM\",\"id\":\"615191\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"alternate_names":[],"attribute_content":[]}
{"type":"Disease","keywords":[],"medgen_id":"C4014668","id":"21303","name":"Combined oxidative phosphorylation deficiency 21","alternate_symbols":[],"symbol":"COXPD21","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0014398\"}","{\"db\":\"OMIM\",\"id\":\"615918\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"420733\"}","{\"db\":\"OMIM\",\"id\":\"615918\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"alternate_names":[],"attribute_content":[]}
{"type":"Disease","keywords":[],"medgen_id":"C1833053","id":"3538","name":"Proprotein convertase 1/3 deficiency","alternate_symbols":[],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0010961\"}","{\"db\":\"OMIM\",\"id\":\"600955\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"71528\"}","{\"db\":\"OMIM\",\"id\":\"600955\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"OBESITY AND ENDOCRINOPATHY DUE TO IMPAIRED PROCESSING OF PROHORMONES\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Proprotein+convertase+1-3+deficiency/9174\",\"ref_field\":\"name\"}"],"alternate_names":["OBESITY AND ENDOCRINOPATHY DUE TO IMPAIRED PROCESSING OF PROHORMONES"],"attribute_content":[]}
{"type":"Disease","keywords":[],"medgen_id":"C3150701","id":"6658","name":"Chromosome 16p11.2 deletion syndrome, 220 kb","alternate_symbols":[],"symbol":"BMIQ16","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0013267\"}","{\"db\":\"OMIM\",\"id\":\"613444\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"261222\"}","{\"db\":\"OMIM\",\"id\":\"613444\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"BODY MASS INDEX QUANTITATIVE TRAIT LOCUS 16\"}","{\"db\":\"OMIM\",\"id\":\"613444\",\"ref_field\":\"symbol\"}"],"alternate_names":["BODY MASS INDEX QUANTITATIVE TRAIT LOCUS 16"],"attribute_content":[]}
{"type":"Disease","keywords":[],"medgen_id":"C3554225","id":"16778","name":"Leptin receptor deficiency","alternate_symbols":[],"symbol":"LEPRD","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0013992\"}","{\"db\":\"OMIM\",\"id\":\"614963\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"179494\"}","{\"db\":\"OMIM\",\"id\":\"614963\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"OBESITY, MORBID\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Leptin+receptor+deficiency/8736\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"614963\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"alternate_names":["OBESITY, MORBID"],"attribute_content":[]}
{"type":"Disease","keywords":[],"medgen_id":"C2751090","id":"11424","name":"Thrombophilia, histidine-rich glycoprotein-related","alternate_symbols":[],"symbol":"THPH11","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0013143\"}","{\"db\":\"OMIM\",\"id\":\"613116\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"217467\"}","{\"db\":\"OMIM\",\"id\":\"142640.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"THROMBOPHILIA DUE TO HISTIDINE-RICH GLYCOPROTEIN DEFICIENCY\"}","{\"db\":\"OMIM\",\"id\":\"142640.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"THROMBOPHILIA DUE TO HISTIDINE-RICH GLYCOPROTEIN DEFICIENCY\"}","{\"db\":\"OMIM\",\"id\":\"142640.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"THROMBOPHILIA DUE TO HISTIDINE-RICH GLYCOPROTEIN DEFICIENCY\"}","{\"db\":\"OMIM\",\"id\":\"613116\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"THROMBOPHILIA DUE TO HISTIDINE-RICH GLYCOPROTEIN DEFICIENCY\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Thrombophilia%2C+histidine-rich+glycoprotein-related/9398\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"613116\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"alternate_names":["THROMBOPHILIA DUE TO HISTIDINE-RICH GLYCOPROTEIN DEFICIENCY"],"attribute_content":[]}
{"type":"Disease","keywords":[],"medgen_id":"C4016368","id":"11098","name":"Central core disease, autosomal recessive","alternate_symbols":[],"xrefs":["{\"db\":\"Genetics Home Reference\",\"id\":\"central-core-disease\",\"ref_field\":\"public_definition\"}"],"public_definition":"Central core disease is a disorder that affects muscles used for movement (skeletal muscles). This condition causes muscle weakness that ranges from barely noticeable to very severe. The severity of muscle weakness may differ even among affected members of the same family.Most people with central core disease experience persistent, mild muscle weakness that does not worsen with time. This weakness affects the muscles near the center of the body (proximal muscles), particularly muscles in the shoulders, upper legs, and hips. Muscle weakness in affected infants can delay the development of motor skills such as sitting, standing, and walking; most people with this condition are able to walk independently. Affected individuals may experience muscle pain (myalgia) or extreme fatigue in response to physical activity (exercise intolerance). Central core disease is also associated with eyes that do not look in the same direction (strabismus), a rounded upper back that also curves to the side (kyphoscoliosis), foot deformities, hip dislocation, and joint deformities called contractures that restrict the movement of certain joints. In severe cases, affected infants experience weakness in the muscles of the face, profound low muscle tone (hypotonia), and serious or life-threatening breathing problems.Many people with central core disease also have an increased risk of developing a severe reaction to certain drugs used during surgery and other invasive procedures. This reaction is called malignant hyperthermia. Malignant hyperthermia occurs in response to some anesthetic gases, which are used to block the sensation of pain, either given alone or in combination with a muscle relaxant that is used to temporarily paralyze a person during a surgical procedure. If given these drugs, people at risk of malignant hyperthermia may experience a rapid increase in heart rate (tachycardia) and body temperature (hyperthermia), abnormally fast breathing (tachypnea), muscle rigidity, breakdown of muscle fibers (rhabdomyolysis), and increased acid levels in the blood and other tissues (acidosis). The complications of malignant hyperthermia can be life-threatening unless they are treated promptly.Central core disease gets its name from disorganized areas called central cores, which are typically found in the center of skeletal muscle cells, but can be at the edges or span the length of the cell, in many affected individuals. These abnormal regions can only been seen when muscle tissue is viewed under a microscope. These central cores are often present in cells with few or no mitochondria, which produce energy within cells. Although the presence of central cores can help doctors diagnose central core disease, it is unclear how they are related to muscle weakness and the other features of this condition.","alternate_names":[],"attribute_content":[]}
{"type":"Disease","keywords":[],"medgen_id":"C3280113","id":"16538","name":"Nephrotic syndrome, type 5, with or without ocular abnormalities","alternate_symbols":[],"symbol":"NPHS5","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0013621\"}","{\"db\":\"OMIM\",\"id\":\"614199\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"306507\"}","{\"db\":\"OMIM\",\"id\":\"150325.0007\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"NEPHROTIC SYNDROME, TYPE 5, WITH OCULAR ABNORMALITIES\"}","{\"db\":\"OMIM\",\"id\":\"150325.0008\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"NEPHROTIC SYNDROME, TYPE 5, WITH OCULAR ABNORMALITIES\"}","{\"db\":\"OMIM\",\"id\":\"150325.0009\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"NEPHROTIC SYNDROME, TYPE 5, WITH OCULAR ABNORMALITIES\"}","{\"db\":\"OMIM\",\"id\":\"150325.0010\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"NEPHROTIC SYNDROME, TYPE 5, WITH OCULAR ABNORMALITIES\"}","{\"db\":\"OMIM\",\"id\":\"150325.0011\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"NEPHROTIC SYNDROME, TYPE 5, WITH OCULAR ABNORMALITIES\"}","{\"db\":\"OMIM\",\"id\":\"150325.0006\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"NEPHROTIC SYNDROME, TYPE 5, WITHOUT OCULAR ABNORMALITIES\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Nephrotic+syndrome%2C+type+5%2C+with+or+without+ocular+abnormalities/8989\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"614199\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"alternate_names":["NEPHROTIC SYNDROME, TYPE 5, WITH OCULAR ABNORMALITIES","NEPHROTIC SYNDROME, TYPE 5, WITHOUT OCULAR ABNORMALITIES"],"attribute_content":[]}
{"type":"Disease","keywords":[],"medgen_id":"C3279614","id":"16543","name":"Platelet-type bleeding disorder 13, susceptibility to","alternate_symbols":[],"symbol":"BDPLT13","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0013524\"}","{\"db\":\"OMIM\",\"id\":\"614009\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"220443\"}","{\"db\":\"OMIM\",\"id\":\"614009\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"BLEEDING DISORDER, SUSCEPTIBILITY TO, DUE TO DEFECTIVE PLATELET THROMBOXANE A2 RECEPTOR\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Bleeding+disorder%2C+platelet-type%2C+13%2C+susceptibility+to/7824\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"614009\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"alternate_names":["BLEEDING DISORDER, SUSCEPTIBILITY TO, DUE TO DEFECTIVE PLATELET THROMBOXANE A2 RECEPTOR"],"attribute_content":[]}
{"type":"Disease","keywords":[],"medgen_id":"C3280953","id":"16825","name":"Hypertriglyceridemia, transient infantile","alternate_symbols":[],"symbol":"HTGTI","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0013771\"}","{\"db\":\"OMIM\",\"id\":\"614480\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"300293\"}","{\"db\":\"Genetic Alliance\",\"id\":\"HYPERTRIGLYCERIDEMIA%2C+TRANSIENT+INFANTILE/8606\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"614480\",\"type\":\"MIM\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"614480\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"public_definition":"Transient infantile hypertriglyceridemia is an autosomal recessive disorder characterized by onset of moderate to severe transient hypertriglyceridemia in infancy that normalizes with age. The hypertriglyceridemia is associated with hepatomegaly, moderately elevated transaminases, persistent fatty liver, and the development of hepatic fibrosis. The long-term outcome of affected individuals is unclear (summary by Basel-Vanagaite et al., 2012).","alternate_names":[],"attribute_content":[]}
{"type":"Disease","keywords":[],"medgen_id":"C3149695","id":"8755","name":"Osteopoikilosis with melorheostosis","alternate_symbols":[],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0015995\"}","{\"db\":\"Orphanet\",\"id\":\"1879\"}"],"alternate_names":[],"attribute_content":[]}
{"type":"Disease","keywords":[],"medgen_id":"C3151062","id":"15775","name":"Infections, recurrent, with encephalopathy, hepatic dysfunction, and cardiovascular malformations","alternate_symbols":[],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0013408\"}","{\"db\":\"OMIM\",\"id\":\"613759\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"306550\"}","{\"db\":\"OMIM\",\"id\":\"613759\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"FADD DEFICIENCY\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Infections%2C+recurrent%2C+with+encephalopathy%2C+hepatic+dysfunction%2C+and+cardiovascular+malformations/8662\",\"ref_field\":\"name\"}"],"alternate_names":["FADD DEFICIENCY"],"attribute_content":[]}
{"type":"Disease","keywords":[],"medgen_id":"C3805604","id":"1299","name":"Foveal hypoplasia and presenile cataract syndrome","alternate_symbols":[],"symbol":"FVH1","gard_id":"406","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0007628\"}","{\"db\":\"OMIM\",\"id\":\"136520\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"2253\"}","{\"db\":\"OMIM\",\"id\":\"136520\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"FOVEAL HYPOPLASIA 1\"}","{\"db\":\"OMIM\",\"id\":\"607108.0012\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"FOVEAL HYPOPLASIA 1\"}","{\"db\":\"OMIM\",\"id\":\"607108.0021\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"FOVEAL HYPOPLASIA 1 WITH ANTERIOR SEGMENT ANOMALIES\"}","{\"db\":\"OMIM\",\"id\":\"136520\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"FOVEAL HYPOPLASIA 1 WITH OR WITHOUT ANTERIOR SEGMENT ANOMALIES AND/OR CATARACT\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"406\",\"ref_field\":\"gard_id\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Foveal+hypoplasia+and+presenile+cataract+syndrome/5284\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"136520\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"alternate_names":["FOVEAL HYPOPLASIA 1","FOVEAL HYPOPLASIA 1 WITH ANTERIOR SEGMENT ANOMALIES","FOVEAL HYPOPLASIA 1 WITH OR WITHOUT ANTERIOR SEGMENT ANOMALIES AND/OR CATARACT"],"attribute_content":[]}
{"type":"Disease","keywords":[],"medgen_id":"C4014954","id":"31878","name":"Severe congenital neutropenia 6, autosomal recessive","alternate_symbols":[],"symbol":"SCN6","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0014456\"}","{\"db\":\"OMIM\",\"id\":\"616022\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"423384\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"severe-congenital-neutropenia\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"616022\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"public_definition":"Severe congenital neutropenia is a condition that causes affected individuals to be prone to recurrent infections. People with this condition have a shortage (deficiency) of neutrophils, a type of white blood cell that plays a role in inflammation and in fighting infection. The deficiency of neutrophils, called neutropenia, is apparent at birth or soon afterward. It leads to recurrent infections beginning in infancy, including infections of the sinuses, lungs, and liver. Affected individuals can also develop fevers and inflammation of the gums (gingivitis) and skin. Approximately 40 percent of affected people have decreased bone density (osteopenia) and may develop osteoporosis, a condition that makes bones progressively more brittle and prone to fracture. In people with severe congenital neutropenia, these bone disorders can begin at any time from infancy through adulthood.Approximately 20 percent of people with severe congenital neutropenia develop certain cancerous conditions of the blood, particularly myelodysplastic syndrome or leukemia during adolescence.Some people with severe congenital neutropenia have additional health problems such as seizures, developmental delay, or heart and genital abnormalities.","alternate_names":[],"attribute_content":[]}
{"type":"Disease","keywords":[],"medgen_id":"C1864843","id":"1538","name":"Combined oxidative phosphorylation deficiency 2","alternate_symbols":[],"symbol":"COXPD2","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0012510\"}","{\"db\":\"OMIM\",\"id\":\"610498\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"254920\"}","{\"db\":\"OMIM\",\"id\":\"610498\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CORPUS CALLOSUM, AGENESIS OF, WITH DYSMORPHISM AND FATAL LACTIC ACIDOSIS\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Combined+oxidative+phosphorylation+deficiency+2/8014\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"610498\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"alternate_names":["CORPUS CALLOSUM, AGENESIS OF, WITH DYSMORPHISM AND FATAL LACTIC ACIDOSIS"],"attribute_content":[]}
{"type":"Disease","keywords":[],"medgen_id":"C3810053","id":"18522","name":"Immunodeficiency 16","alternate_symbols":[],"symbol":"IMD16","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0014268\"}","{\"db\":\"OMIM\",\"id\":\"615593\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"431149\"}","{\"db\":\"OMIM\",\"id\":\"615593\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"OX40 DEFICIENCY\"}","{\"db\":\"OMIM\",\"id\":\"615593\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"alternate_names":["OX40 DEFICIENCY"],"attribute_content":[]}
{"type":"Disease","keywords":[],"medgen_id":"C1850395","id":"5639","name":"Neuropathy, hereditary sensory, with spastic paraplegia, autosomal recessive","alternate_symbols":[],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0009748\"}","{\"db\":\"OMIM\",\"id\":\"256840\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"139578\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Neuropathy%2C+hereditary+sensory%2C+with+spastic+paraplegia%2C+autosomal+recessive/9003\",\"ref_field\":\"name\"}"],"alternate_names":[],"attribute_content":[]}
{"type":"Disease","keywords":[],"medgen_id":"C3279722","id":"16113","name":"Myopathy, distal, 4","alternate_symbols":[],"symbol":"MPD4","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0013550\"}","{\"db\":\"OMIM\",\"id\":\"614065\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"63273\"}","{\"db\":\"OMIM\",\"id\":\"614065\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"WILLIAMS DISTAL MYOPATHY\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Myopathy%2C+distal%2C+4/8952\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"614065\",\"type\":\"MIM\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"614065\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"public_definition":"Williams distal myopathy is an autosomal dominant slowly progressive muscular disorder characterized by distal muscle weakness and atrophy affecting the upper and lower limbs. Onset occurs around the third to fourth decades of life, and patients remain ambulatory even after long disease duration. Muscle biopsy shows nonspecific changes with no evidence of rods, necrosis, or inflammation (summary by Duff et al., 2011).\r\nMutation in the FLNC gene can also cause myofibrillar myopathy-5 (MFM5; 609524), which shows a different pattern of muscle involvement and different histologic changes.","alternate_names":["WILLIAMS DISTAL MYOPATHY"],"attribute_content":[]}
{"type":"Disease","keywords":[],"medgen_id":"C1835931","id":"107","name":"Alpha/beta T-cell lymphopenia with gamma/delta T-cell expansion, severe cytomegalovirus infection, and autoimmunity","alternate_symbols":[],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0012359\"}","{\"db\":\"OMIM\",\"id\":\"609889\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"231154\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Alpha-beta+T-cell+lymphopenia+with+gamma-delta+T-cell+expansion%2C+severe+cytomegalovirus+infection%2C+and+autoimmunity/7672\",\"ref_field\":\"name\"}"],"alternate_names":[],"attribute_content":[]}
{"type":"Disease","keywords":[],"medgen_id":"C3809470","id":"18300","name":"Epidermolysis bullosa simplex, autosomal recessive 2","alternate_symbols":[],"symbol":"EBSB2","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0014180\"}","{\"db\":\"OMIM\",\"id\":\"615425\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"412181\"}","{\"db\":\"OMIM\",\"id\":\"615425\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"alternate_names":[],"attribute_content":[]}
{"type":"Finding","keywords":[],"medgen_id":"C2242577","id":"29934","name":"Oromandibular dystonia","alternate_symbols":[],"xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001494\",\"type\":\"secondary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0012048\",\"type\":\"primary\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0019771\"}","{\"db\":\"Orphanet\",\"id\":\"93958\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0012048\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Cranial dystonia\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0012048\",\"ref_field\":\"name\"}"],"alternate_names":["Cranial dystonia"],"attribute_content":[]}
{"type":"Disease","keywords":[],"medgen_id":"C3553989","id":"17423","name":"Spinal muscular atrophy, distal, autosomal recessive, 5","alternate_symbols":[],"symbol":"DSMA5","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0013947\"}","{\"db\":\"OMIM\",\"id\":\"614881\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"314485\"}","{\"db\":\"OMIM\",\"id\":\"614881\",\"type\":\"MIM\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"614881\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"public_definition":"DSMA5 is an autosomal recessive neurologic disorder characterized by young adult onset of slowly progressive distal muscle weakness and atrophy resulting in gait impairment and loss of reflexes due to impaired function of motor nerves. Sensation and cognition are not impaired (summary by Blumen et al., 2012).\r\nFor a general phenotypic description and a discussion of genetic heterogeneity of distal SMA, see HMN1 (182960).","alternate_names":[],"attribute_content":[]}
{"type":"Finding","keywords":[],"medgen_id":"C0008489","id":"22827","name":"Chorea","alternate_symbols":[],"xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0002072\",\"type\":\"primary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0002397\",\"type\":\"secondary\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0001595\"}","{\"db\":\"Orphanet\",\"id\":\"1429\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0002072\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Choreatic disease\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0001595\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Choreatic disease\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0002072\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Choreic movements\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0002072\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Choreiform movements\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0002072\",\"ref_field\":\"name\"}"],"alternate_names":["Choreatic disease","Choreic movements","Choreiform movements"],"attribute_content":[]}
{"type":"Disease","keywords":[],"medgen_id":"C1720779","id":"323","name":"Apolipoprotein C2 deficiency","alternate_symbols":[],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0008810\"}","{\"db\":\"OMIM\",\"id\":\"207750\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"309020\"}","{\"db\":\"Orphanet\",\"id\":\"444490\"}","{\"db\":\"OMIM\",\"id\":\"207750\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"APOC2 DEFICIENCY\"}","{\"db\":\"OMIM\",\"id\":\"207750\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"C-II ANAPOLIPOPROTEINEMIA\"}","{\"db\":\"OMIM\",\"id\":\"207750\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HYPERLIPOPROTEINEMIA, TYPE IB\"}","{\"db\":\"OMIM\",\"id\":\"608083.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HYPERLIPOPROTEINEMIA, TYPE IB\"}","{\"db\":\"OMIM\",\"id\":\"608083.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HYPERLIPOPROTEINEMIA, TYPE IB\"}","{\"db\":\"OMIM\",\"id\":\"608083.0004\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HYPERLIPOPROTEINEMIA, TYPE IB\"}","{\"db\":\"OMIM\",\"id\":\"608083.0005\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HYPERLIPOPROTEINEMIA, TYPE IB\"}","{\"db\":\"OMIM\",\"id\":\"608083.0006\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HYPERLIPOPROTEINEMIA, TYPE IB\"}","{\"db\":\"OMIM\",\"id\":\"608083.0007\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HYPERLIPOPROTEINEMIA, TYPE IB\"}","{\"db\":\"OMIM\",\"id\":\"608083.0008\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HYPERLIPOPROTEINEMIA, TYPE IB\"}","{\"db\":\"OMIM\",\"id\":\"608083.0011\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HYPERLIPOPROTEINEMIA, TYPE IB\"}","{\"db\":\"OMIM\",\"id\":\"608083.0012\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HYPERLIPOPROTEINEMIA, TYPE IB\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Apolipoprotein+C2+deficiency/7704\",\"ref_field\":\"name\"}"],"alternate_names":["APOC2 DEFICIENCY","C-II ANAPOLIPOPROTEINEMIA","HYPERLIPOPROTEINEMIA, TYPE IB"],"attribute_content":[]}
{"type":"Disease","keywords":[],"medgen_id":"C4225173","id":"34886","name":"Immunodeficiency, common variable, 13","alternate_symbols":[],"symbol":"CVID13","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0014810\"}","{\"db\":\"OMIM\",\"id\":\"616873\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"317473\"}","{\"db\":\"OMIM\",\"id\":\"616873\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"alternate_names":[],"attribute_content":[]}
{"type":"Disease","keywords":[],"medgen_id":"C2676023","id":"2351","name":"Hypercarotenemia and vitamin a deficiency, autosomal dominant","alternate_symbols":[],"symbol":"HCVAD","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0007272\"}","{\"db\":\"OMIM\",\"id\":\"115300\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"199285\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Hypercarotenemia+and+vitamin+a+deficiency%2C+autosomal+dominant/8579\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"115300\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"alternate_names":[],"attribute_content":[]}
{"type":"Disease","keywords":[],"medgen_id":"C4225260","id":"34432","name":"Immunodeficiency 44","alternate_symbols":[],"symbol":"IMD44","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0014715\"}","{\"db\":\"OMIM\",\"id\":\"616636\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"431166\"}","{\"db\":\"OMIM\",\"id\":\"616636\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"alternate_names":[],"attribute_content":[]}
{"type":"Disease","keywords":[],"medgen_id":"C2675227","id":"1593","name":"Endocrine-cerebroosteodysplasia","alternate_symbols":[],"symbol":"ECO","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0012980\"}","{\"db\":\"OMIM\",\"id\":\"612651\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"199332\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Endocrine-cerebroosteodysplasia/8311\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"612651\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"alternate_names":[],"attribute_content":[]}
{"type":"Disease","keywords":[],"medgen_id":"C3553529","id":"17310","name":"Combined oxidative phosphorylation deficiency 10","alternate_symbols":[],"symbol":"COXPD10","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0013865\"}","{\"db\":\"OMIM\",\"id\":\"614702\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"314637\"}","{\"db\":\"OMIM\",\"id\":\"614702\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CARDIOMYOPATHY, INFANTILE HYPERTROPHIC MITOCHONDRIAL, AND LACTIC ACIDOSIS\"}","{\"db\":\"OMIM\",\"id\":\"614702\",\"type\":\"MIM\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"614702\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"public_definition":"COXPD10 is an autosomal recessive disorder resulting in variable defects of mitochondrial oxidative respiration. Affected individuals present in infancy with hypertrophic cardiomyopathy and lactic acidosis. The severity is variable, but can be fatal in the most severe cases (summary by Ghezzi et al., 2012).\r\nFor a discussion of genetic heterogeneity of combined oxidative phosphorylation deficiency, see COXPD1 (609060).","alternate_names":["CARDIOMYOPATHY, INFANTILE HYPERTROPHIC MITOCHONDRIAL, AND LACTIC ACIDOSIS"],"attribute_content":[]}
{"type":"Disease","keywords":[],"medgen_id":"C3151898","id":"6802","name":"Mitochondrial myopathy, infantile, transient","alternate_symbols":[],"symbol":"MMIT","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0010780\"}","{\"db\":\"OMIM\",\"id\":\"500009\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"254864\"}","{\"db\":\"OMIM\",\"id\":\"500009\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"COX DEFICIENCY MYOPATHY, INFANTILE, TRANSIENT\"}","{\"db\":\"OMIM\",\"id\":\"500009\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MITOCHONDRIAL MYOPATHY, INFANTILE, TRANSIENT, DUE TO RESPIRATORY CHAIN DEFICIENCY\"}","{\"db\":\"OMIM\",\"id\":\"500009\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"RESPIRATORY CHAIN DEFICIENCY, INFANTILE, TRANSIENT\"}","{\"db\":\"OMIM\",\"id\":\"500009\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"alternate_names":["COX DEFICIENCY MYOPATHY, INFANTILE, TRANSIENT","MITOCHONDRIAL MYOPATHY, INFANTILE, TRANSIENT, DUE TO RESPIRATORY CHAIN DEFICIENCY","RESPIRATORY CHAIN DEFICIENCY, INFANTILE, TRANSIENT"],"attribute_content":[]}
{"type":"Disease","keywords":[],"medgen_id":"C3150921","id":"15711","name":"Microcephaly, postnatal progressive, with seizures and brain atrophy","alternate_symbols":[],"gard_id":"10995","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0013351\"}","{\"db\":\"OMIM\",\"id\":\"613668\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"402364\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"10995\",\"ref_field\":\"gard_id\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Microcephaly%2C+postnatal+progressive%2C+with+seizures+and+brain+atrophy/8871\",\"ref_field\":\"name\"}"],"alternate_names":[],"attribute_content":[]}
{"type":"Disease","keywords":[],"medgen_id":"C2751855","id":"6770","name":"Hypomyelination, global cerebral","alternate_symbols":[],"symbol":"EIEE39","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0013056\"}","{\"db\":\"OMIM\",\"id\":\"612949\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"353217\"}","{\"db\":\"OMIM\",\"id\":\"603667.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 39\"}","{\"db\":\"OMIM\",\"id\":\"603667.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 39\"}","{\"db\":\"OMIM\",\"id\":\"612949\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 39\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Hypomyelination%2C+global+cerebral/8618\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"612949\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"alternate_names":["EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 39"],"attribute_content":[]}
{"type":"Disease","keywords":[],"medgen_id":"C3808553","id":"17013","name":"Bone marrow failure syndrome 1","alternate_symbols":[],"symbol":"BMFS1","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0013851\"}","{\"db\":\"OMIM\",\"id\":\"614675\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"314399\"}","{\"db\":\"OMIM\",\"id\":\"614675\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"alternate_names":[],"attribute_content":[]}
{"type":"Disease","keywords":[],"medgen_id":"C1867968","id":"4010","name":"Porphyria cutanea tarda, type I","alternate_symbols":[],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0008295\"}","{\"db\":\"OMIM\",\"id\":\"176090\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"101330\"}","{\"db\":\"Orphanet\",\"id\":\"443057\"}","{\"db\":\"OMIM\",\"id\":\"176090\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"PCT, ''SPORADIC'' TYPE\"}","{\"db\":\"OMIM\",\"id\":\"176090\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"PCT, TYPE I\"}"],"alternate_names":["PCT, ''SPORADIC'' TYPE","PCT, TYPE I"],"attribute_content":[]}
{"type":"Disease","keywords":[],"medgen_id":"C0342549","id":"3529","name":"Gonadotropin-independent familial sexual precocity","alternate_symbols":[],"gard_id":"4475","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0008303\"}","{\"db\":\"OMIM\",\"id\":\"176410\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"3000\"}","{\"db\":\"OMIM\",\"id\":\"176410\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"TESTOTOXICOSIS, FAMILIAL\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"4475\",\"ref_field\":\"gard_id\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Testotoxicosis/7032\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"237818003\",\"ref_field\":\"name\"}"],"alternate_names":["Familial Testotoxicosis (subtype)","Pubertas Praecox","TESTOTOXICOSIS, FAMILIAL","Testotoxicosis"],"attribute_content":[]}
{"type":"Disease","keywords":[],"medgen_id":"C3809753","id":"18376","name":"Mental retardation, autosomal recessive 38","alternate_symbols":[],"symbol":"MRT38","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0014224\"}","{\"db\":\"OMIM\",\"id\":\"615516\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"329195\"}","{\"db\":\"OMIM\",\"id\":\"615516\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"alternate_names":[],"attribute_content":[]}
{"type":"Disease","keywords":[],"medgen_id":"C3279875","id":"16110","name":"Cortical malformations, occipital","alternate_symbols":[],"symbol":"OCCM","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0013583\"}","{\"db\":\"OMIM\",\"id\":\"614115\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"280640\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Cortical+malformations%2C+occipital/8099\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"614115\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"alternate_names":[],"attribute_content":[]}
{"type":"Disease","keywords":[],"medgen_id":"C4305072","id":"41651","name":"X-linked intellectual disability, Van Esch type","alternate_symbols":[],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0015601\"}","{\"db\":\"Orphanet\",\"id\":\"163976\"}"],"alternate_names":[],"attribute_content":[]}
{"type":"Disease","keywords":[],"medgen_id":"C3809008","id":"17945","name":"Hypomyelination with brainstem and spinal cord involvement and leg spasticity","alternate_symbols":[],"symbol":"HBSL","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0014115\"}","{\"db\":\"OMIM\",\"id\":\"615281\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"363412\"}","{\"db\":\"OMIM\",\"id\":\"615281\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"ASPARTYL-tRNA SYNTHETASE DEFICIENCY\"}","{\"db\":\"OMIM\",\"id\":\"615281\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"alternate_names":["ASPARTYL-tRNA SYNTHETASE DEFICIENCY"],"attribute_content":[]}
{"type":"Disease","keywords":[],"medgen_id":"C1853392","id":"2315","name":"Interleukin 2 receptor, alpha, deficiency of","alternate_symbols":[],"symbol":"IMD41","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0011664\"}","{\"db\":\"OMIM\",\"id\":\"606367\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"169100\"}","{\"db\":\"OMIM\",\"id\":\"606367\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CD25 DEFICIENCY\"}","{\"db\":\"OMIM\",\"id\":\"606367\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"IL2RA DEFICIENCY\"}","{\"db\":\"OMIM\",\"id\":\"147730.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"IMMUNODEFICIENCY 41 WITH LYMPHOPROLIFERATION AND AUTOIMMUNITY\"}","{\"db\":\"OMIM\",\"id\":\"147730.0004\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"IMMUNODEFICIENCY 41 WITH LYMPHOPROLIFERATION AND AUTOIMMUNITY\"}","{\"db\":\"OMIM\",\"id\":\"147730.0005\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"IMMUNODEFICIENCY 41 WITH LYMPHOPROLIFERATION AND AUTOIMMUNITY\"}","{\"db\":\"OMIM\",\"id\":\"147730.0006\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"IMMUNODEFICIENCY 41 WITH LYMPHOPROLIFERATION AND AUTOIMMUNITY\"}","{\"db\":\"OMIM\",\"id\":\"147730.0007\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"IMMUNODEFICIENCY 41 WITH LYMPHOPROLIFERATION AND AUTOIMMUNITY\"}","{\"db\":\"OMIM\",\"id\":\"606367\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"IMMUNODEFICIENCY 41 WITH LYMPHOPROLIFERATION AND AUTOIMMUNITY\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Interleukin+2+receptor%2C+alpha%2C+deficiency+of/8676\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"606367\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"alternate_names":["CD25 DEFICIENCY","IL2RA DEFICIENCY","IMMUNODEFICIENCY 41 WITH LYMPHOPROLIFERATION AND AUTOIMMUNITY"],"attribute_content":[]}
{"type":"Disease","keywords":[],"medgen_id":"C3810043","id":"18501","name":"Immunodeficiency 15","alternate_symbols":[],"symbol":"IMD15B","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0014267\"}","{\"db\":\"OMIM\",\"id\":\"615592\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"397787\"}","{\"db\":\"OMIM\",\"id\":\"603258.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"IMMUNODEFICIENCY 15B\"}","{\"db\":\"OMIM\",\"id\":\"603258.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"IMMUNODEFICIENCY 15B\"}","{\"db\":\"OMIM\",\"id\":\"615592\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"IMMUNODEFICIENCY 15B\"}","{\"db\":\"OMIM\",\"id\":\"615592\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"alternate_names":["IMMUNODEFICIENCY 15B"],"attribute_content":[]}
{"type":"Disease","keywords":[],"medgen_id":"C3810107","id":"18548","name":"Immunodeficiency 17","alternate_symbols":[],"symbol":"IMD17","gard_id":"9521","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0014276\"}","{\"db\":\"OMIM\",\"id\":\"615607\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"169082\"}","{\"db\":\"OMIM\",\"id\":\"615607\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CD3-GAMMA DEFICIENCY\"}","{\"db\":\"OMIM\",\"id\":\"615607\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"SCID-LIKE IMMUNODEFICIENCY, T CELL-PARTIAL, B CELL-POSITIVE, NK CELL-POSITIVE\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"9521\",\"ref_field\":\"gard_id\"}","{\"db\":\"OMIM\",\"id\":\"615607\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"alternate_names":["CD3-GAMMA DEFICIENCY","SCID-LIKE IMMUNODEFICIENCY, T CELL-PARTIAL, B CELL-POSITIVE, NK CELL-POSITIVE"],"attribute_content":[]}
{"type":"Disease","keywords":[],"medgen_id":"C4014233","id":"18717","name":"Immunodeficiency 22","alternate_symbols":[],"symbol":"IMD22","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0014334\"}","{\"db\":\"OMIM\",\"id\":\"615758\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"280142\"}","{\"db\":\"OMIM\",\"id\":\"615758\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"alternate_names":[],"attribute_content":[]}
{"type":"Disease","keywords":[],"medgen_id":"C3809583","id":"18315","name":"Immunodeficiency 12","alternate_symbols":[],"symbol":"IMD12","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0014197\"}","{\"db\":\"OMIM\",\"id\":\"615468\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"397964\"}","{\"db\":\"OMIM\",\"id\":\"615468\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"alternate_names":[],"attribute_content":[]}
{"type":"Disease","keywords":[],"medgen_id":"C3550963","id":"17515","name":"Hypothyroidism, central, and testicular enlargement","alternate_symbols":[],"symbol":"CHTE","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0010475\"}","{\"db\":\"OMIM\",\"id\":\"300888\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"329235\"}","{\"db\":\"OMIM\",\"id\":\"300137.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HYPOTHYROIDISM, CENTRAL, WITH TESTICULAR ENLARGEMENT\"}","{\"db\":\"OMIM\",\"id\":\"300137.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HYPOTHYROIDISM, CENTRAL, WITH TESTICULAR ENLARGEMENT\"}","{\"db\":\"OMIM\",\"id\":\"300137.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HYPOTHYROIDISM, CENTRAL, WITH TESTICULAR ENLARGEMENT\"}","{\"db\":\"OMIM\",\"id\":\"300137.0004\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HYPOTHYROIDISM, CENTRAL, WITH TESTICULAR ENLARGEMENT\"}","{\"db\":\"OMIM\",\"id\":\"300137.0005\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HYPOTHYROIDISM, CENTRAL, WITH TESTICULAR ENLARGEMENT\"}","{\"db\":\"OMIM\",\"id\":\"300137.0006\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HYPOTHYROIDISM, CENTRAL, WITH TESTICULAR ENLARGEMENT\"}","{\"db\":\"OMIM\",\"id\":\"300137.0007\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HYPOTHYROIDISM, CENTRAL, WITH TESTICULAR ENLARGEMENT\"}","{\"db\":\"OMIM\",\"id\":\"300888\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HYPOTHYROIDISM, CENTRAL, WITH TESTICULAR ENLARGEMENT\"}","{\"db\":\"OMIM\",\"id\":\"300888\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"alternate_names":["HYPOTHYROIDISM, CENTRAL, WITH TESTICULAR ENLARGEMENT"],"attribute_content":[]}
{"type":"Disease","keywords":[],"medgen_id":"C3810324","id":"18640","name":"Morbid obesity and spermatogenic failure","alternate_symbols":[],"symbol":"MOSPGF","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0014309\"}","{\"db\":\"OMIM\",\"id\":\"615703\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"397615\"}","{\"db\":\"OMIM\",\"id\":\"615703\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"alternate_names":[],"attribute_content":[]}
{"type":"Disease","keywords":[],"medgen_id":"C4310764","id":"35689","name":"Neutropenia, severe congenital, 7, autosomal recessive","alternate_symbols":[],"symbol":"SCN7","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0014865\"}","{\"db\":\"OMIM\",\"id\":\"617014\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"420702\"}","{\"db\":\"OMIM\",\"id\":\"617014\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"alternate_names":[],"attribute_content":[]}
{"type":"Disease","keywords":[],"medgen_id":"C4014435","id":"18793","name":"Mental retardation, autosomal dominant 26","alternate_symbols":[],"symbol":"MRD26","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0014361\"}","{\"db\":\"OMIM\",\"id\":\"615834\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"352490\"}","{\"db\":\"OMIM\",\"id\":\"615834\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"alternate_names":[],"attribute_content":[]}
{"type":"Finding","keywords":[],"medgen_id":"C0151723","id":"23417","name":"Hypomagnesemia","alternate_symbols":[],"gard_id":"2906","xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0002917\",\"type\":\"primary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0003284\",\"type\":\"secondary\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0018100\"}","{\"db\":\"OMIM\",\"id\":\"PS602014\",\"type\":\"Phenotypic series\"}","{\"db\":\"Orphanet\",\"id\":\"34526\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0002917\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Low blood magnesium levels\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"2906\",\"ref_field\":\"gard_id\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0002917\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"PS602014\",\"type\":\"Phenotypic series\",\"ref_field\":\"name\"}"],"alternate_names":["Low blood magnesium levels"],"attribute_content":[]}
{"type":"Disease","keywords":[],"medgen_id":"C4225379","id":"33206","name":"Lipoyltransferase 1 deficiency","alternate_symbols":[],"symbol":"LIPT1D","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0014576\"}","{\"db\":\"OMIM\",\"id\":\"616299\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"401862\"}","{\"db\":\"OMIM\",\"id\":\"616299\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"alternate_names":[],"attribute_content":[]}
{"type":"Disease","keywords":[],"medgen_id":"CN277969","id":"43766","name":"Hereditary angioedema with normal C1Inh","alternate_symbols":[],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0033947\"}","{\"db\":\"Orphanet\",\"id\":\"528647\"}","{\"db\":\"OMIM\",\"id\":\"610618\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"ANGIONEUROTIC EDEMA, HEREDITARY, WITH NORMAL C1 INHIBITOR CONCENTRATION AND FUNCTION\"}","{\"db\":\"OMIM\",\"id\":\"610618\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HAE WITH NORMAL C1 INHIBITOR CONCENTRATION AND FUNCTION\"}","{\"db\":\"SNOMED CT\",\"id\":\"427167008\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Hereditary angioneurotic edema with normal C1 esterase inhibitor activity\"}"],"alternate_names":["ANGIONEUROTIC EDEMA, HEREDITARY, WITH NORMAL C1 INHIBITOR CONCENTRATION AND FUNCTION","HAE WITH NORMAL C1 INHIBITOR CONCENTRATION AND FUNCTION","Hereditary angioneurotic edema with normal C1 esterase inhibitor activity"],"attribute_content":[]}
{"type":"Disease","keywords":[],"medgen_id":"C1970211","id":"4175","name":"Distal spinal muscular atrophy, autosomal recessive 4","alternate_symbols":[],"symbol":"DSMA4","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0012608\"}","{\"db\":\"OMIM\",\"id\":\"611067\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"206580\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Distal+spinal+muscular+atrophy%2C+autosomal+recessive+4/8274\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"611067\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"alternate_names":[],"attribute_content":[]}
{"type":"Disease","keywords":[],"medgen_id":"C1855860","id":"5301","name":"Hypoglycemia, neonatal, simulating foetopathia diabetica","alternate_symbols":[],"symbol":"HIHGHH","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0009416\"}","{\"db\":\"OMIM\",\"id\":\"240900\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"293964\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Hypoglycemia%2C+neonatal%2C+simulating+foetopathia+diabetica/8611\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"240900\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"alternate_names":[],"attribute_content":[]}
{"type":"Disease","keywords":["Neoplasm"],"medgen_id":"C3152204","id":"10004","name":"Cutaneous malignant melanoma 8","alternate_symbols":[],"symbol":"CMM8","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0013759\"}","{\"db\":\"OMIM\",\"id\":\"614456\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"293822\"}","{\"db\":\"OMIM\",\"id\":\"614456\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MELANOMA AND RENAL CELL CARCINOMA, SUSCEPTIBILITY TO\"}","{\"db\":\"OMIM\",\"id\":\"156845.0009\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MELANOMA, CUTANEOUS MALIGNANT, SUSCEPTIBILITY TO, 8\"}","{\"db\":\"OMIM\",\"id\":\"601800\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MELANOMA, CUTANEOUS MALIGNANT, SUSCEPTIBILITY TO, 8\"}","{\"db\":\"OMIM\",\"id\":\"606933.0009\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MELANOMA, CUTANEOUS MALIGNANT, SUSCEPTIBILITY TO, 8\"}","{\"db\":\"OMIM\",\"id\":\"614456\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MELANOMA, CUTANEOUS MALIGNANT, SUSCEPTIBILITY TO, 8\"}","{\"db\":\"OMIM\",\"id\":\"614456\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"alternate_names":["MELANOMA AND RENAL CELL CARCINOMA, SUSCEPTIBILITY TO","MELANOMA, CUTANEOUS MALIGNANT, SUSCEPTIBILITY TO, 8"],"attribute_content":[]}
{"type":"Disease","keywords":[],"medgen_id":"C3810285","id":"18620","name":"Myopathy with extrapyramidal signs","alternate_symbols":[],"symbol":"MPXPS","gard_id":"12978","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0014300\"}","{\"db\":\"OMIM\",\"id\":\"615673\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"401768\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"12978\",\"ref_field\":\"gard_id\"}","{\"db\":\"OMIM\",\"id\":\"615673\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"alternate_names":[],"attribute_content":[]}
{"type":"Disease","keywords":[],"medgen_id":"C3809339","id":"18259","name":"Combined oxidative phosphorylation deficiency 16","alternate_symbols":[],"symbol":"COXPD16","gard_id":"12892","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0014162\"}","{\"db\":\"OMIM\",\"id\":\"615395\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"352563\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"12892\",\"ref_field\":\"gard_id\"}","{\"db\":\"OMIM\",\"id\":\"615395\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"alternate_names":[],"attribute_content":[]}
{"type":"Disease","keywords":[],"medgen_id":"C1857682","id":"1539","name":"Combined oxidative phosphorylation deficiency 4","alternate_symbols":[],"symbol":"COXPD4","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0012534\"}","{\"db\":\"OMIM\",\"id\":\"610678\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"254925\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Combined+oxidative+phosphorylation+deficiency+4/8016\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"610678\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"alternate_names":[],"attribute_content":[]}
{"type":"Disease","keywords":[],"medgen_id":"C4014722","id":"21316","name":"Sting-associated vasculopathy, infantile-onset","alternate_symbols":[],"symbol":"SAVI","gard_id":"12357","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0014405\"}","{\"db\":\"OMIM\",\"id\":\"615934\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"425120\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"12357\",\"ref_field\":\"gard_id\"}","{\"db\":\"OMIM\",\"id\":\"615934\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"alternate_names":[],"attribute_content":[]}
{"type":"Finding","keywords":[],"medgen_id":"C4024851","id":"26247","name":"Punctate palmoplantar hyperkeratosis","alternate_symbols":[],"xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0007530\",\"type\":\"primary\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0017675\"}","{\"db\":\"Orphanet\",\"id\":\"307967\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0007530\",\"ref_field\":\"name\"}"],"alternate_names":[],"attribute_content":[]}
{"type":"Disease","keywords":[],"medgen_id":"C3553709","id":"17362","name":"Myopathy, centronuclear, 4","alternate_symbols":[],"symbol":"CNM4","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0013890\"}","{\"db\":\"OMIM\",\"id\":\"614807\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"319160\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"centronuclear-myopathy\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"614807\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"public_definition":"Centronuclear myopathy is a condition characterized by muscle weakness (myopathy) and wasting (atrophy) in the skeletal muscles, which are the muscles used for movement. The severity of centronuclear myopathy varies among affected individuals, even among members of the same family.People with centronuclear myopathy begin experiencing muscle weakness at any time from birth to early adulthood. The muscle weakness slowly worsens over time and can lead to delayed development of motor skills, such as crawling or walking; muscle pain during exercise; and difficulty walking. Some affected individuals may need wheelchair assistance as the muscles atrophy and weakness becomes more severe. In rare instances, the muscle weakness improves over time.Some people with centronuclear myopathy experience mild to severe breathing problems related to the weakness of muscles needed for breathing. People with centronuclear myopathy may have droopy eyelids (ptosis) and weakness in other facial muscles, including the muscles that control eye movement. People with this condition may also have foot abnormalities, a high arch in the roof of the mouth (high-arched palate), and abnormal side-to-side curvature of the spine (scoliosis). Rarely, individuals with centronuclear myopathy have a weakened heart muscle (cardiomyopathy), disturbances in nerve function (neuropathy), or intellectual disability.A key feature of centronuclear myopathy is the displacement of the nucleus in muscle cells, which can be viewed under a microscope. Normally the nucleus is found at the edges of the rod-shaped muscle cells, but in people with centronuclear myopathy the nucleus is located in the center of these cells. How the change in location of the nucleus affects muscle cell function is unknown.","alternate_names":[],"attribute_content":[]}
{"type":"Disease","keywords":[],"medgen_id":"C3808920","id":"17840","name":"Hypochromic microcytic anemia with iron overload 2","alternate_symbols":[],"symbol":"AHMIO2","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0014094\"}","{\"db\":\"OMIM\",\"id\":\"615234\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"300298\"}","{\"db\":\"OMIM\",\"id\":\"615234\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"alternate_names":[],"attribute_content":[]}
{"type":"Disease","keywords":[],"medgen_id":"C3553943","id":"17416","name":"T-cell immunodeficiency, recurrent infections, and autoimmunity with or without cardiac malformations","alternate_symbols":[],"symbol":"TIIAC","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0013934\"}","{\"db\":\"OMIM\",\"id\":\"614868\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"314689\"}","{\"db\":\"OMIM\",\"id\":\"614868\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MST1 DEFICIENCY\"}","{\"db\":\"OMIM\",\"id\":\"614868\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"STK4 DEFICIENCY\"}","{\"db\":\"OMIM\",\"id\":\"604965.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"T-CELL IMMUNODEFICIENCY, RECURRENT INFECTIONS, AUTOIMMUNITY, AND CARDIAC MALFORMATIONS\"}","{\"db\":\"OMIM\",\"id\":\"604965.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"T-CELL IMMUNODEFICIENCY, RECURRENT INFECTIONS, AUTOIMMUNITY, AND CARDIAC MALFORMATIONS\"}","{\"db\":\"OMIM\",\"id\":\"604965.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"T-CELL IMMUNODEFICIENCY, RECURRENT INFECTIONS, AUTOIMMUNITY, AND CARDIAC MALFORMATIONS\"}","{\"db\":\"OMIM\",\"id\":\"614868\",\"type\":\"MIM\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"614868\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"public_definition":"STK4 deficiency results in a primary T-cell immunodeficiency syndrome characterized by progressive loss of naive T cells, recurrent bacterial, viral, and fungal infections, warts, and abscesses, autoimmune manifestations, and cardiac malformations, including atrial septal defect (Abdollahpour et al., 2012; Nehme et al., 2012).","alternate_names":["MST1 DEFICIENCY","STK4 DEFICIENCY","T-CELL IMMUNODEFICIENCY, RECURRENT INFECTIONS, AUTOIMMUNITY, AND CARDIAC MALFORMATIONS"],"attribute_content":[]}
{"type":"Disease","keywords":[],"medgen_id":"C3281234","id":"16882","name":"Combined oxidative phosphorylation deficiency 9","alternate_symbols":[],"symbol":"COXPD9","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0013811\"}","{\"db\":\"OMIM\",\"id\":\"614582\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"319509\"}","{\"db\":\"Genetic Alliance\",\"id\":\"COMBINED+OXIDATIVE+PHOSPHORYLATION+DEFICIENCY+9/8021\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"614582\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"alternate_names":[],"attribute_content":[]}
{"type":"Disease","keywords":[],"medgen_id":"C3554499","id":"17657","name":"Primary autosomal recessive microcephaly 10","alternate_symbols":[],"symbol":"MCPH10","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0014043\"}","{\"db\":\"OMIM\",\"id\":\"615095\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"329228\"}","{\"db\":\"OMIM\",\"id\":\"615095\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"alternate_names":[],"attribute_content":[]}
{"type":"Disease","keywords":[],"medgen_id":"C3151753","id":"6671","name":"Combined oxidative phosphorylation deficiency 6","alternate_symbols":[],"symbol":"COXPD6","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0010437\"}","{\"db\":\"OMIM\",\"id\":\"300816\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"238329\"}","{\"db\":\"OMIM\",\"id\":\"300816\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"ENCEPHALOMYOPATHY, MITOCHONDRIAL, X-LINKED\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Combined+oxidative+phosphorylation+deficiency+6/8018\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"300816\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"alternate_names":["ENCEPHALOMYOPATHY, MITOCHONDRIAL, X-LINKED"],"attribute_content":[]}
{"type":"Disease","keywords":[],"medgen_id":"C3280866","id":"16823","name":"Thiamine metabolism dysfunction syndrome 5 (episodic encephalopathy type)","alternate_symbols":[],"symbol":"THMD5","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0013761\"}","{\"db\":\"OMIM\",\"id\":\"614458\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"293955\"}","{\"db\":\"OMIM\",\"id\":\"614458\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"ENCEPHALOPATHY, EPISODIC, DUE TO THIAMINE PYROPHOSPHOKINASE DEFICIENCY\"}","{\"db\":\"OMIM\",\"id\":\"614458\",\"type\":\"MIM\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"614458\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"public_definition":"Episodic encephalopathy due to thiamine pyrophosphokinase deficiency is an autosomal recessive metabolic disorder due to an inborn error of thiamine metabolism. The phenotype is highly variable, but in general, affected individuals have onset in early childhood of acute encephalopathic episodes associated with increased serum and CSF lactate. These episodes result in progressive neurologic dysfunction manifest as gait disturbances, ataxia, dystonia, and spasticity, which in some cases may result in loss of ability to walk. Cognitive function is usually preserved, although mildly delayed development has been reported. These episodes are usually associated with infection and metabolic decompensation. Some patients may have recovery of some neurologic deficits (summary by Mayr et al., 2011).\r\nFor a discussion of genetic heterogeneity of disorders due to thiamine metabolism dysfunction, see THMD1 (249270).","alternate_names":["ENCEPHALOPATHY, EPISODIC, DUE TO THIAMINE PYROPHOSPHOKINASE DEFICIENCY"],"attribute_content":[]}
{"type":"Disease","keywords":[],"medgen_id":"C3150154","id":"808","name":"16p11.2 deletion syndrome","alternate_symbols":[],"gard_id":"10740","xrefs":["{\"db\":\"Gene\",\"id\":\"100187724\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0012756\"}","{\"db\":\"OMIM\",\"id\":\"611913\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"261197\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK11167\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"16p11.2 Microdeletion\"}","{\"db\":\"OMIM\",\"id\":\"611913\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CHROMOSOME 16p11.2 DELETION SYNDROME, 593-KB\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"10740\",\"ref_field\":\"gard_id\"}","{\"db\":\"Genetic Alliance\",\"id\":\"16p11.2+deletion+syndrome/9529\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK11167\",\"ref_field\":\"public_definition\"}"],"public_definition":"The 16p11.2 recurrent microdeletion phenotype is characterized by developmental delay, intellectual disability, and/or autism spectrum disorder (ASD). Developmental delays are related to diminished language, cognitive function, and motor impairments. While IQ scores range from mild intellectual disability to normal, those with IQ scores in the average range typically have other developmental issues such as language delay or ASD. Expressive language appears to be more affected than receptive language. Seizures are observed in approximately 20% of individuals with the recurrent microdeletion. Macrocephaly is common, usually becoming apparent by age two years. Chiari malformations/cerebellar ectopia are the most frequently observed structural brain abnormalities. In individuals with the 16p11.2 recurrent microdeletion the frequency of birth defects of all types is slightly increased, with vertebral anomalies appearing to be most frequent.","content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301775\",\"@Source\":\"PubMed\"},{\"$\":\"NBK11167\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"29334453\",\"@Source\":\"PubMed\"},{\"$\":\"NBK475803\",\"@Source\":\"BookShelf\"}]}]}","alternate_names":["16p11.2 Microdeletion","CHROMOSOME 16p11.2 DELETION SYNDROME, 593-KB","Chromosome 16p11.2 deletion syndrome"],"attribute_content":[]}
{"type":"Disease","keywords":[],"medgen_id":"C0268155","id":"5172","name":"Deficiency of galactokinase","alternate_symbols":[],"symbol":"GALAC2","gard_id":"2422","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0009255\"}","{\"db\":\"OMIM\",\"id\":\"230200\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"352\"}","{\"db\":\"Orphanet\",\"id\":\"79237\"}","{\"db\":\"OMIM\",\"id\":\"230200\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"GALACTOSEMIA II\"}","{\"db\":\"OMIM\",\"id\":\"604313.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"GALACTOSEMIA II\"}","{\"db\":\"OMIM\",\"id\":\"604313.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"GALACTOSEMIA II\"}","{\"db\":\"OMIM\",\"id\":\"604313.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"GALACTOSEMIA II\"}","{\"db\":\"OMIM\",\"id\":\"604313.0004\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"GALACTOSEMIA II\"}","{\"db\":\"OMIM\",\"id\":\"604313.0005\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"GALACTOSEMIA II\"}","{\"db\":\"OMIM\",\"id\":\"604313.0006\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"GALACTOSEMIA II\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"2422\",\"ref_field\":\"gard_id\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Galactokinase+Deficiency/2970\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"124302001\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"230200\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"content":"{\"Citation\":[{\"@Abbrev\":\"ACMG ACT Sheet, 2010\",\"@Type\":\"practice guideline\",\"CitationText\":{\"$\":\"American College of Medical Genetics ACT SHEETs, Primary or Secondary Hypergalactosemia, 2010\"},\"URL\":{\"$\":\"https://www.ncbi.nlm.nih.gov/books/NBK55827/bin/Galactose_GALT.pdf\"}},{\"@Abbrev\":\"ACMG Algorithm, 2009\",\"@Type\":\"practice guideline\",\"CitationText\":{\"$\":\"American College of Medical Genetics Algorithm, Primary or Secondary Hypergalactosemia, 2009\"},\"URL\":{\"$\":\"https://www.ncbi.nlm.nih.gov/books/NBK55827/bin/Visio-GALT.pdf\"}}]}","alternate_names":["GALACTOSEMIA II","Galactosemia 2","Hereditary galactokinase deficiency"],"attribute_content":[]}
{"type":"Disease","keywords":[],"medgen_id":"C0002986","id":"1790","name":"Fabry disease","disease_mechanism":"Fabry disease is due to inactivating mutations in the X-linked GLA gene resulting in deficiency of the enzyme Alpha Galactosidase-A.","alternate_symbols":[],"gard_id":"6400","xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001071\",\"type\":\"primary\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0010526\"}","{\"db\":\"OMIM\",\"id\":\"301500\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"324\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001071\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Angiokeratoma corporis diffusum\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001071\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Fabry syndrome\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Fabry+Disease/2690\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Fabry's disease\"}","{\"db\":\"SNOMED CT\",\"id\":\"16652001\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Fabry's disease\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000500007\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"6400\",\"ref_field\":\"gard_id\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"fabry-disease\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1292\",\"ref_field\":\"public_definition\"}"],"public_definition":"Fabry disease results from deficient activity of the enzyme alpha-galactosidase A (a-Gal A) and progressive lysosomal deposition of globotriaosylceramide (GL-3) in cells throughout the body. The classic form, occurring in males with less than 1% a-Gal A enzyme activity, usually has its onset in childhood or adolescence with periodic crises of severe pain in the extremities (acroparesthesia), the appearance of vascular cutaneous lesions (angiokeratomas), sweating abnormalities (anhidrosis, hypohidrosis, and rarely hyperhidrosis), characteristic corneal and lenticular opacities, and proteinuria. Gradual deterioration of renal function to end-stage renal disease (ESRD) usually occurs in men in the third to fifth decade. In middle age, most males successfully treated for ESRD develop cardiac and/or cerebrovascular disease, a major cause of morbidity and mortality. Heterozygous females typically have milder symptoms at a later age of onset than males. Rarely, they may be relatively asymptomatic throughout a normal life span or may have symptoms as severe as those observed in males with the classic phenotype. In contrast, males with greater than 1% a-Gal A activity may have: (1) a cardiac variant phenotype that usually presents in the sixth to eighth decade with left ventricular hypertrophy, cardiomyopathy and arrhythmia, and proteinuria, but without ESRD; or (2) a renal variant phenotype, associated with ESRD but without the skin lesions or pain; or (3) cerebrovascular disease presenting as stroke or transient ischemic attack.","content":"{\"Citation\":[{\"@Type\":\"general\",\"ID\":{\"$\":\"3009617\",\"@Source\":\"pmc\"}},{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301469\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1292\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"HFSA, 2010\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"20610207\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"NSGC, 2002\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"12735292\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"Eng et al., 2006\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"16980809\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"Salviati et al, 2010\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"2869001\",\"@Source\":\"pmc\"}},{\"@Abbrev\":\"EuroGentest, 2011\",\"@Type\":\"Translational/Evidence-based\",\"ID\":{\"$\":\"21934708\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ACMG, 2013\",\"@Type\":\"Recommendation\",\"ID\":{\"$\":\"23788249\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"AHA/ASA, 2014\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"25355838\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"NSGC, 2013\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"23860966\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ESC, 2014\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"25173338\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ACMG, 2015\",\"@Type\":\"Recommendation\",\"ID\":{\"$\":\"25356965\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ACMG, 2016\",\"@Type\":\"Recommendation\",\"ID\":[{\"$\":\"27854360\",\"@Source\":\"PubMed\"},{\"$\":\"10.1038/gim.2016.190\",\"@Source\":\"DOI\"}]}]}","alternate_names":["Alpha-galactosidase A deficiency","Anderson-Fabry disease","Angiokeratoma corporis diffusum","Angiokeratoma, diffuse","Ceramide trihexosidase deficiency","Ceramide trihexosidosis","Fabry syndrome","Fabry's disease","GLA deficiency","Hereditary dystopic lipidosis"],"attribute_content":["{\"Attribute\":{\"$\":\"loss of function\",\"@Type\":\"disease mechanism\",\"@integerValue\":\"273\"},\"XRef\":[{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000246735\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000260631\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000520063\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000520447\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000528528\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000552214\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000556520\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000558532\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000551442\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000325415\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000512526\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000528276\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000528500\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000528536\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000556501\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000514924\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000520414\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000528516\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000505068\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000507480\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000507942\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000522527\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000568367\"}]}"]}
{"type":"Disease","keywords":[],"medgen_id":"C1854488","id":"4179","name":"Spinocerebellar ataxia type 13","alternate_symbols":[],"symbol":"SCA13","gard_id":"9611","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0011529\"}","{\"db\":\"OMIM\",\"id\":\"605259\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"98768\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"9611\",\"ref_field\":\"gard_id\"}","{\"db\":\"GeneTests\",\"id\":\"195045\",\"ref_field\":\"name\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0011529\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1225\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"605259\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"public_definition":"Spinocerebellar ataxia type 13 (SCA13) is a phenotypic spectrum that includes both non-progressive infantile-onset ataxia and progressive childhood-onset and adult-onset cerebellar ataxia. Three phenotypes are seen: Cerebellar hypoplasia with non-progressive infantile-onset limb, truncal, and gait ataxia with mild-to-moderate intellectual disability and occasionally seizures and/or psychiatric manifestations. Cognition and motor skills improve over time. Childhood-onset slowly progressive cerebellar atrophy with slowly progressive cerebellar ataxia and dysarthria, delayed motor milestones, and mild-to-moderate intellectual disability. Adult-onset progressive cerebellar atrophy with progressive ataxia and spasticity.","content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301404\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1225\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301317\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1138\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"EFNS, 2010\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"20050888\",\"@Source\":\"PubMed\"}}]}","alternate_names":["Cerebellar ataxia, autosomal dominant with mental retardation","Spinocerebellar Ataxia Type13"],"attribute_content":[]}
{"type":"Disease","keywords":[],"medgen_id":"C0023473","id":"2683","name":"Chronic myelogenous leukemia, BCR-ABL1 positive","alternate_symbols":[],"symbol":"CML","gard_id":"6105","xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0005506\",\"type\":\"primary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0005544\",\"type\":\"secondary\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0011996\"}","{\"db\":\"MeSH\",\"id\":\"D015464\"}","{\"db\":\"OMIM\",\"id\":\"608232\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"521\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0005506\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Chronic myelocytic leukemia\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0005506\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Chronic myelogenous leukemia\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Chronic+Myeloid+Leukemia/1622\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Chronic myeloid leukemia\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0005506\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Chronic myeloid leukemia\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"6105\",\"ref_field\":\"gard_id\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0011996\",\"ref_field\":\"name\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"chronic-myeloid-leukemia\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"608232\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"public_definition":"Chronic myeloid leukemia is a slow-growing cancer of the blood-forming tissue (bone marrow). Normal bone marrow produces red blood cells (erythrocytes) that carry oxygen, white blood cells (leukocytes) that protect the body from infection, and platelets (thrombocytes) that are involved in blood clotting. In chronic myeloid leukemia, the bone marrow produces too many white blood cells. Initially, these cells function relatively normally. However, as the condition progresses, immature white blood cells called myeloblasts (or blasts) accumulate in the blood and bone marrow. The overgrowth of myeloblasts impairs development of other blood cells, leading to a shortage of red blood cells (anemia) and platelets.Chronic myeloid leukemia usually begins after age 60. Common features include excessive tiredness (fatigue), fever, and weight loss. Many affected individuals develop an enlarged spleen (splenomegaly), which can cause a feeling of fullness in the abdomen and a loss of appetite. About half of people with chronic myeloid leukemia do not initially have any signs and symptoms and are diagnosed when a blood test is performed for another reason.The condition consists of three phases: the chronic phase, the accelerated phase, and the blast phase (or blast crisis). In the chronic phase, the number of mature white blood cells is elevated, and myeloblasts account for less than 10 percent of blood cells. Signs and symptoms of the condition during this phase are typically mild or absent and worsen slowly. The chronic phase can last from months to years. In the accelerated phase, the number of myeloblasts is slightly higher, making up 10 to 29 percent of blood cells. The signs and symptoms continue to worsen. The accelerated phase usually lasts 4 to 6 months, although it is skipped in some affected individuals. In blast crisis, 30 percent or more of blood or bone marrow cells are myeloblasts. Signs and symptoms are most severe in this phase, including a massively enlarged spleen, bone pain, and weight loss. Serious infections and uncontrolled bleeding can be life-threatening.","content":"{\"Citation\":{\"@Abbrev\":\"IBFM, 2014\",\"@Type\":\"Recommendation\",\"ID\":{\"$\":\"24976289\",\"@Source\":\"PubMed\"}}}","alternate_names":["Chronic granulocytic leukemia","Chronic myelocytic leukemia","Chronic myelogenous leukemia","Chronic myeloid leukemia"],"attribute_content":[]}
{"type":"Disease","keywords":[],"medgen_id":"C0019243","id":"18760","name":"Hereditary angioneurotic edema","alternate_symbols":[],"symbol":"HAE","gard_id":"5979","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0019623\"}","{\"db\":\"Orphanet\",\"id\":\"91378\"}","{\"db\":\"Illumina Clinical Services Laboratory,Illumina\",\"id\":\"38957\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Hereditary Angioedema\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"5979\",\"ref_field\":\"gard_id\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Hereditary+angioedema/3342\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"82966003\",\"ref_field\":\"name\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"hereditary-angioedema\",\"ref_field\":\"public_definition\"}"],"public_definition":"Hereditary angioedema is a disorder characterized by recurrent episodes of severe swelling (angioedema). The most common areas of the body to develop swelling are the limbs, face, intestinal tract, and airway. Minor trauma or stress may trigger an attack, but swelling often occurs without a known trigger. Episodes involving the intestinal tract cause severe abdominal pain, nausea, and vomiting. Swelling in the airway can restrict breathing and lead to life-threatening obstruction of the airway. About one-third of people with this condition develop a non-itchy rash called erythema marginatum during an attack.Symptoms of hereditary angioedema typically begin in childhood and worsen during puberty. On average, untreated individuals have an attack every 1 to 2 weeks, and most episodes last for about 3 to 4 days. The frequency and duration of attacks vary greatly among people with hereditary angioedema, even among people in the same family.There are three types of hereditary angioedema, called types I, II, and III, which can be distinguished by their underlying causes and levels of a protein called C1 inhibitor in the blood. The different types have similar signs and symptoms. Type III was originally thought to occur only in women, but families with affected males have been identified.","content":"{\"Citation\":{\"@Abbrev\":\"Caballero et al., 2012\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"22197274\",\"@Source\":\"PubMed\"}}}","alternate_names":["Angioedemas, Hereditary","Hereditary Angioedema"],"attribute_content":[]}
{"type":"Disease","keywords":[],"medgen_id":"C3495498","id":"1311","name":"Familial hypertrophic cardiomyopathy 1","alternate_symbols":[],"symbol":"CMH1","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0013476\"}","{\"db\":\"OMIM\",\"id\":\"192600\",\"type\":\"MIM\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Familial+hypertrophic+cardiomyopathy+1/8382\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"192600\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"public_definition":"Hypertrophic cardiomyopathy (HCM) is typically defined by the presence of unexplained left ventricular hypertrophy (LVH). Such LVH occurs in a non-dilated ventricle in the absence of other cardiac or systemic disease capable of producing the observed magnitude of increased LV wall thickness, such as pressure overload (e.g., long-standing hypertension, aortic stenosis) or storage/infiltrative disorders (e.g., Fabry disease, amyloidosis). The clinical manifestations of HCM range from asymptomatic LVH to progressive heart failure to sudden cardiac death (SCD), and vary from individual to individual even within the same family. Common symptoms include shortness of breath (particularly with exertion), chest pain, palpitations, orthostasis, presyncope, and syncope. Most often the LVH of HCM becomes apparent during adolescence or young adulthood, although it may also develop late in life, in infancy, or in childhood.","content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301559\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1385\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301725\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1768\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"EuroGenetest, 2011\",\"@Type\":\"Translational/Evidence-based\",\"ID\":{\"$\":\"21267010\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ACMG, 2013\",\"@Type\":\"Recommendation\",\"ID\":{\"$\":\"23788249\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"AHRQ, 2013\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"NBK248310\",\"@Source\":\"BookShelf\"}},{\"@Abbrev\":\"ESC, 2014\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"25173338\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ACMG, 2015\",\"@Type\":\"Recommendation\",\"ID\":{\"$\":\"25356965\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ACMG, 2016\",\"@Type\":\"Recommendation\",\"ID\":[{\"$\":\"27854360\",\"@Source\":\"PubMed\"},{\"$\":\"10.1038/gim.2016.190\",\"@Source\":\"DOI\"}]}]}","alternate_names":["MYH7-Related Familial Hypertrophic Cardiomyopathy"],"attribute_content":["{\"Attribute\":{\"$\":\"C0949658\",\"@Type\":\"CUI, rejected\"}}"]}
{"type":"Disease","keywords":[],"medgen_id":"C4551952","id":"5591","name":"Myopathy, centronuclear, 1","alternate_symbols":[],"symbol":"CNM1","gard_id":"12719","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0008048\"}","{\"db\":\"MeSH\",\"id\":\"D020914\"}","{\"db\":\"OMIM\",\"id\":\"160150\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"169189\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0008048\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Autosomal dominant centronuclear myopathy\"}","{\"db\":\"OMIM\",\"id\":\"160150\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MYOTUBULAR MYOPATHY, AUTOSOMAL DOMINANT\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"12719\",\"ref_field\":\"gard_id\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Myopathy%2C+centronuclear%2C+1/8947\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"160150\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"content":"{\"Citation\":{\"@Abbrev\":\"EuroGenetest, 2012\",\"@Type\":\"Translational/Evidence-based\",\"ID\":{\"$\":\"22617344\",\"@Source\":\"PubMed\"}}}","alternate_names":["Autosomal dominant centronuclear myopathy","MYOTUBULAR MYOPATHY, AUTOSOMAL DOMINANT"],"attribute_content":[]}
{"type":"Disease","keywords":[],"medgen_id":"C4759870","id":"5961","name":"Spinocerebellar ataxia, autosomal recessive, with axonal neuropathy 1","alternate_symbols":[],"symbol":"SCAN1","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0011801\"}","{\"db\":\"OMIM\",\"id\":\"607250\",\"type\":\"MIM\"}","{\"db\":\"OMIM\",\"id\":\"607250\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301284\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1105\",\"@Source\":\"BookShelf\"}]}}","alternate_names":[],"attribute_content":[]}
{"type":"Disease","keywords":[],"medgen_id":"C1838126","id":"1058","name":"Brachydactyly-Mental Retardation syndrome","alternate_symbols":[],"symbol":"BDMR","gard_id":"10202","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0010886\"}","{\"db\":\"OMIM\",\"id\":\"600430\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"1001\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"10202\",\"ref_field\":\"gard_id\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Brachydactyly-Mental+Retardation+syndrome/1525\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"600430\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301337\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1158\",\"@Source\":\"BookShelf\"}]}}","alternate_names":["Albright hereditary osteodystrophy-like syndrome"],"attribute_content":[]}
{"type":"Disease","keywords":[],"medgen_id":"C1853942","id":"4809","name":"Neonatal intrahepatic cholestasis caused by citrin deficiency","alternate_symbols":[],"symbol":"NICCD","gard_id":"10214","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0011601\"}","{\"db\":\"OMIM\",\"id\":\"605814\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"247598\"}","{\"db\":\"OMIM\",\"id\":\"605814\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CITRULLINEMIA, TYPE II, NEONATAL-ONSET, WITH OR WITHOUT FAILURE TO THRIVE AND DYSLIPIDEMIA\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"10214\",\"ref_field\":\"gard_id\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Citrin+Deficiency/1648\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1181\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"605814\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"public_definition":"Citrin deficiency can manifest in newborns or infants as neonatal intrahepatic cholestasis caused by citrin deficiency (NICCD), in older children as failure to thrive and dyslipidemia caused by citrin deficiency (FTTDCD), and in adults as recurrent hyperammonemia with neuropsychiatric symptoms in citrullinemia type II (CTLN2). Often citrin deficiency is characterized by strong preference for protein-rich and/or lipid-rich foods and aversion to carbohydrate-rich foods. NICCD. Children younger than age one year have a history of low birth weight with growth restriction and transient intrahepatic cholestasis, hepatomegaly, diffuse fatty liver, and parenchymal cellular infiltration associated with hepatic fibrosis, variable liver dysfunction, hypoproteinemia, decreased coagulation factors, hemolytic anemia, and/or hypoglycemia. NICCD is generally not severe and symptoms often resolve by age one year with appropriate treatment, although liver transplantation has been required in rare instances. FTTDCD. Beyond age one year, many children with citrin deficiency develop a protein-rich and/or lipid-rich food preference and aversion to carbohydrate-rich foods. Clinical abnormalities may include growth restriction, hypoglycemia, pancreatitis, severe fatigue, anorexia, and impaired quality of life. Laboratory changes are dyslipidemia, increased lactate-to-pyruvate ratio, higher levels of urinary oxidative stress markers, and considerable deviation in tricarboxylic acid (TCA) cycle metabolites. One or more decades later, some individuals with NICCD or FTTDCD develop CTLN2. CTLN2. Presentation is sudden and usually between ages 20 and 50 years. Manifestations are recurrent hyperammonemia with neuropsychiatric symptoms including nocturnal delirium, aggression, irritability, hyperactivity, delusions, disorientation, restlessness, drowsiness, loss of memory, flapping tremor, convulsive seizures, and coma. Symptoms are often provoked by alcohol and sugar intake, medication, and/or surgery. Affected individuals may or may not have a prior history of NICCD or FTTDCD.","content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301360\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1181\",\"@Source\":\"BookShelf\"}]}}","alternate_names":["CITRULLINEMIA, TYPE II, NEONATAL-ONSET, WITH OR WITHOUT FAILURE TO THRIVE AND DYSLIPIDEMIA","Neonatal-onset citrullinemia type 2","Neonatal-onset citrullinemia type II"],"attribute_content":[]}
{"type":"Disease","keywords":[],"medgen_id":"CN262442","id":"43000","name":"Rothmund-Thomson syndrome type 1","alternate_symbols":[],"symbol":"RTS1","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0016368\"}","{\"db\":\"OMIM\",\"id\":\"618625\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"221008\"}","{\"db\":\"OMIM\",\"id\":\"618625\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"POIKILODERMA ATROPHICANS AND CATARACT\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1237\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"618625\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"public_definition":"Rothmund-Thomson syndrome (RTS) is characterized by a rash that progresses to poikiloderma; sparse hair, eyelashes, and/or eyebrows; small size; skeletal and dental abnormalities; juvenile cataracts; and an increased risk for cancer, especially osteosarcoma. A variety of benign and malignant hematologic abnormalities have been reported in affected individuals. The rash of RTS typically develops between ages three and six months (occasionally as late as age two years) as erythema, swelling, and blistering on the face, subsequently spreading to the buttocks and extremities. The rash evolves over months to years into the chronic pattern of reticulated hypo- and hyperpigmentation, telangiectasias, and punctate atrophy (collectively known as poikiloderma) that persist throughout life. Hyperkeratotic lesions occur in approximately one third of individuals. Skeletal abnormalities can include radial ray defects, ulnar defects, absent or hypoplastic patella, and osteopenia.","content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301415\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1237\",\"@Source\":\"BookShelf\"}]}}","alternate_names":["POIKILODERMA ATROPHICANS AND CATARACT"],"attribute_content":[]}
{"type":"Disease","keywords":[],"medgen_id":"C3810394","id":"18675","name":"Palmoplantar keratoderma, nonepidermolytic, focal or diffuse","alternate_symbols":[],"symbol":"PPKNEFD","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0014327\"}","{\"db\":\"OMIM\",\"id\":\"615735\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"402003\"}","{\"db\":\"OMIM\",\"id\":\"612315.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"PALMOPLANTAR KERATODERMA, FOCAL OR DIFFUSE\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1280\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"615735\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"public_definition":"Pachyonychia congenita (PC) is characterized by hypertrophic nail dystrophy, painful palmoplantar keratoderma and blistering, oral leukokeratosis, pilosebaceous cysts (including steatocystoma and vellus hair cysts), palmoplantar hyperhydrosis, and follicular keratoses on the trunk and extremities.","content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301457\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1280\",\"@Source\":\"BookShelf\"}]}}","alternate_names":["PALMOPLANTAR KERATODERMA, FOCAL OR DIFFUSE"],"attribute_content":[]}
{"type":"Disease","keywords":[],"medgen_id":"C4014700","id":"21315","name":"Encephalopathy, progressive, with or without lipodystrophy","alternate_symbols":[],"symbol":"PELD","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0014402\"}","{\"db\":\"OMIM\",\"id\":\"615924\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"363400\"}","{\"db\":\"OMIM\",\"id\":\"606158.0018\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"ENCEPHALOPATHY, PROGRESSIVE, WITH LIPODYSTROPHY\"}","{\"db\":\"OMIM\",\"id\":\"606158.0019\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"ENCEPHALOPATHY, PROGRESSIVE, WITH LIPODYSTROPHY\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1307\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"615924\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"public_definition":"The spectrum of BSCL2-related neurologic disorders includes Silver syndrome and variants of Charcot-Marie-Tooth neuropathy type 2, distal hereditary motor neuropathy (dHMN) type V, and spastic paraplegia 17. Features of these disorders include onset of symptoms ranging from the first to the seventh decade, slow disease progression, upper motor neuron involvement (gait disturbance with pyramidal signs ranging from mild to severe spasticity with hyperreflexia in the lower limbs and variable extensor plantar responses), lower motor neuron involvement (amyotrophy of the peroneal muscles and small muscles of the hand), and pes cavus and other foot deformities. Disease severity is variable among and within families.","content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301484\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1307\",\"@Source\":\"BookShelf\"}]}}","alternate_names":["ENCEPHALOPATHY, PROGRESSIVE, WITH LIPODYSTROPHY"],"attribute_content":[]}
{"type":"Disease","keywords":[],"medgen_id":"C3554367","id":"17561","name":"Epidermolysis bullosa, nonspecific, autosomal recessive","alternate_symbols":[],"symbol":"EBNS","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0014014\"}","{\"db\":\"OMIM\",\"id\":\"615028\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"412189\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1369\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"615028\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"public_definition":"Epidermolysis bullosa simplex (EBS) is characterized by fragility of the skin (and mucosal epithelia in some cases) that results in non-scarring blisters and erosions caused by minor mechanical trauma. The current classification of epidermolysis bullosa (EB) includes two major types and 17 minor subtypes of EBS; all share the common feature of blistering above the dermal-epidermal junction at the ultrastructural level. The four most common subtypes of EBS are the focus of this GeneReview: EBS, localized (EBS-loc; previously known as Weber-Cockayne type). EBS, generalized intermediate (EBS-gen intermed; previously known as Koebner type). EBS-with mottled pigmentation (EBS-MP). EBS, generalized severe (EBS-gen sev; previously known as Dowling-Meara type). The phenotypes for these subtypes range from relatively mild blistering of the hands and feet to more generalized blistering, which can be fatal. In EBS-loc, blisters are rarely present or minimal at birth and may occur on the knees and shins with crawling or on the feet at approximately age 18 months; some individuals manifest the disease in adolescence or early adulthood. Blisters are usually confined to the hands and feet, but can occur anywhere if trauma is significant. In EBS, gen intermed, blisters may be present at birth or develop within the first few months of life. Involvement is more widespread than in EBS-loc, but generally milder than in EBS-gen sev. In EBS-MP, skin fragility is evident at birth and clinically indistinguishable from EBS-gen sev; over time, progressive brown pigmentation interspersed with hypopigmented spots develops on the trunk and extremities, with the pigmentation disappearing in adult life. Focal palmar and plantar hyperkeratoses may occur. In EBS-gen sev, onset is usually at birth; severity varies greatly, both among and within families. Widespread and severe blistering and/or multiple grouped clumps of small blisters are typical and hemorrhagic blisters are common. Improvement occurs during mid- to late childhood. Progressive hyperkeratosis of the palms and soles begins in childhood and may be the major complaint of affected individuals in adult life. Nail dystrophy and milia are common. Both hyper- and hypopigmentation can occur. Mucosal involvement in EBS-gen sev may interfere with feeding, especially in neonates and infants. Blistering can be severe enough to result in neonatal or infant death.","content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301543\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1369\",\"@Source\":\"BookShelf\"}]}}","alternate_names":[],"attribute_content":[]}
{"type":"Disease","keywords":[],"medgen_id":"C3151266","id":"16024","name":"Familial hypertrophic cardiomyopathy 19","alternate_symbols":[],"symbol":"CMH19","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0013476\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0013476\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Hypertrophic cardiomyopathy 19\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Cardiomyopathy%2C+familial+hypertrophic%2C+19/7900\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"613875\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301559\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1385\",\"@Source\":\"BookShelf\"}]}}","alternate_names":["Hypertrophic cardiomyopathy 19"],"attribute_content":[]}
{"type":"Disease","keywords":[],"medgen_id":"C3281247","id":"16886","name":"Bent bone dysplasia syndrome","alternate_symbols":[],"symbol":"BBDS","gard_id":"10965","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0013815\"}","{\"db\":\"OMIM\",\"id\":\"614592\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"313855\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"10965\",\"ref_field\":\"gard_id\"}","{\"db\":\"Genetic Alliance\",\"id\":\"BENT+BONE+DYSPLASIA+SYNDROME/7809\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"614592\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301628\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1455\",\"@Source\":\"BookShelf\"}]}}","alternate_names":[],"attribute_content":[]}
{"type":"Disease","keywords":[],"medgen_id":"C3150986","id":"15768","name":"Early infantile epileptic encephalopathy 7","alternate_symbols":[],"symbol":"EIEE7","gard_id":"13060","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0013387\"}","{\"db\":\"OMIM\",\"id\":\"613720\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"439218\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"13060\",\"ref_field\":\"gard_id\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Epileptic+encephalopathy%2C+early+infantile%2C+7/8345\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK32534\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"613720\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"public_definition":"KCNQ2-related disorders represent a continuum of overlapping neonatal epileptic phenotypes caused by a heterozygous pathogenic variant in KCNQ2. The clinical features of KCNQ2-related disorders range from KCNQ2-related benign familial neonatal epilepsy (KCNQ2-BFNE) at the mild end to KCNQ2-related neonatal epileptic encephalopathy (KCNQ2-NEE) at the severe end. KCNQ2-BFNE is characterized by a wide spectrum of seizure types (tonic or apneic episodes, focal clonic activity, or autonomic changes) that start in otherwise healthy infants between the second and eighth day of life and spontaneously disappear between the first and the sixth to 12th month of life. Motor activity may be confined to one body part, migrate to other body regions, or generalize. Seizures are generally brief, lasting one to two minutes. Rarely, KCNQ2-BFNE may evolve into status epilepticus. About 10%-15% of individuals with BFNE develop epileptic seizures later in life. KCNQ2-NEE is characterized by multiple daily seizures beginning in the first week of life that are mostly tonic, with associated focal motor and autonomic features. Seizures generally cease between ages nine months and four years. At onset, EEG shows a burst-suppression pattern or multifocal epileptiform activity; early brain MRI can show basal ganglia and thalamic hyperintensities that later resolve. Moderate to severe developmental impairment is present.","content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20437616\",\"@Source\":\"PubMed\"},{\"$\":\"NBK32534\",\"@Source\":\"BookShelf\"}]}}","alternate_names":["KCNQ2-Related Neonatal Epileptic Encephalopathy"],"attribute_content":[]}
{"type":"Disease","keywords":[],"medgen_id":"C3149750","id":"2956","name":"Mitochondrial DNA depletion syndrome 2","alternate_symbols":[],"symbol":"MTDPS2","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0012301\"}","{\"db\":\"OMIM\",\"id\":\"609560\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"254875\"}","{\"db\":\"OMIM\",\"id\":\"609560\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MITOCHONDRIAL DNA DEPLETION MYOPATHY, TK2-RELATED\"}","{\"db\":\"OMIM\",\"id\":\"188250.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MITOCHONDRIAL DNA DEPLETION SYNDROME 2 (MYOPATHIC TYPE)\"}","{\"db\":\"OMIM\",\"id\":\"188250.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MITOCHONDRIAL DNA DEPLETION SYNDROME 2 (MYOPATHIC TYPE)\"}","{\"db\":\"OMIM\",\"id\":\"188250.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MITOCHONDRIAL DNA DEPLETION SYNDROME 2 (MYOPATHIC TYPE)\"}","{\"db\":\"OMIM\",\"id\":\"188250.0004\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MITOCHONDRIAL DNA DEPLETION SYNDROME 2 (MYOPATHIC TYPE)\"}","{\"db\":\"OMIM\",\"id\":\"188250.0005\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MITOCHONDRIAL DNA DEPLETION SYNDROME 2 (MYOPATHIC TYPE)\"}","{\"db\":\"OMIM\",\"id\":\"188250.0006\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MITOCHONDRIAL DNA DEPLETION SYNDROME 2 (MYOPATHIC TYPE)\"}","{\"db\":\"OMIM\",\"id\":\"609560\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MITOCHONDRIAL DNA DEPLETION SYNDROME 2 (MYOPATHIC TYPE)\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK114628\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"TK2-Related Mitochondrial DNA Depletion Syndrome, Myopathic Form\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Mitochondrial+DNA+depletion+syndrome+2/8897\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK114628\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"609560\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"public_definition":"TK2-related mitochondrial DNA (mtDNA) maintenance defect is a phenotypic continuum that ranges from severe to mild. To date, approximately 107 individuals with a molecularly confirmed diagnosis have been reported. Three main subtypes of presentation have been described: Infantile-onset myopathy with neurologic involvement and rapid progression to early death. Affected individuals experience progressive muscle weakness leading to respiratory failure. Some individuals develop dysarthria, dysphagia, and/or hearing loss. Cognitive function is typically spared. Juvenile/childhood onset with generalized proximal weakness and survival to at least 13 years. Late-/adult-onset myopathy with facial and limb weakness and mtDNA deletions. Some affected individuals develop respiratory insufficiency, chronic progressive external ophthalmoplegia, dysphagia, and dysarthria.","content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"23230576\",\"@Source\":\"PubMed\"},{\"$\":\"NBK114628\",\"@Source\":\"BookShelf\"}]}}","alternate_names":["MITOCHONDRIAL DNA DEPLETION MYOPATHY, TK2-RELATED","MITOCHONDRIAL DNA DEPLETION SYNDROME 2 (MYOPATHIC TYPE)","TK2-Related Mitochondrial DNA Depletion Syndrome, Myopathic Form"],"attribute_content":[]}
{"type":"Disease","keywords":[],"medgen_id":"C2749861","id":"2810","name":"Mitochondrial DNA depletion syndrome, encephalomyopathic form, with renal tubulopathy","alternate_symbols":[],"symbol":"MTDPS8A","gard_id":"13200","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0012792\"}","{\"db\":\"OMIM\",\"id\":\"612075\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"255235\"}","{\"db\":\"OMIM\",\"id\":\"604712.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MITOCHONDRIAL DNA DEPLETION SYNDROME 8A (ENCEPHALOMYOPATHIC TYPE WITH RENAL TUBULOPATHY)\"}","{\"db\":\"OMIM\",\"id\":\"604712.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MITOCHONDRIAL DNA DEPLETION SYNDROME 8A (ENCEPHALOMYOPATHIC TYPE WITH RENAL TUBULOPATHY)\"}","{\"db\":\"OMIM\",\"id\":\"604712.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MITOCHONDRIAL DNA DEPLETION SYNDROME 8A (ENCEPHALOMYOPATHIC TYPE WITH RENAL TUBULOPATHY)\"}","{\"db\":\"OMIM\",\"id\":\"604712.0004\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MITOCHONDRIAL DNA DEPLETION SYNDROME 8A (ENCEPHALOMYOPATHIC TYPE WITH RENAL TUBULOPATHY)\"}","{\"db\":\"OMIM\",\"id\":\"604712.0005\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MITOCHONDRIAL DNA DEPLETION SYNDROME 8A (ENCEPHALOMYOPATHIC TYPE WITH RENAL TUBULOPATHY)\"}","{\"db\":\"OMIM\",\"id\":\"604712.0007\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MITOCHONDRIAL DNA DEPLETION SYNDROME 8A (ENCEPHALOMYOPATHIC TYPE WITH RENAL TUBULOPATHY)\"}","{\"db\":\"OMIM\",\"id\":\"612075\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MITOCHONDRIAL DNA DEPLETION SYNDROME 8A (ENCEPHALOMYOPATHIC TYPE WITH RENAL TUBULOPATHY)\"}","{\"db\":\"OMIM\",\"id\":\"612075\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MITOCHONDRIAL DNA DEPLETION SYNDROME, ENCEPHALOMYOPATHIC, WITH RENAL TUBULOPATHY, AUTOSOMAL RECESSIVE\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"13200\",\"ref_field\":\"gard_id\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Mitochondrial+DNA+depletion+syndrome%2C+encephalomyopathic+form%2C+with+renal+tubulopathy/8900\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK195854\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"612075\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"public_definition":"RRM2B-related mitochondrial disease can be grouped by disease pathogenesis, phenotype, and mode of inheritance into two major types: mitochondrial DNA (mtDNA) depletion and multiple mtDNA deletions. Mitochondrial DNA depletion usually manifests as severe multisystem disease (encephalomyopathy with proximal renal tubulopathy) and is often fatal in early life. Inheritance is autosomal recessive. Multiple mtDNA deletions cause tissue-specific cytochrome c oxidase (COX) deficiency. Inheritance can be either autosomal recessive (with progressive external ophthalmoplegia [PEO] and multisystem involvement manifesting during early childhood/adulthood) or autosomal dominant (with less severe, often tissue-specific manifestations [e.g., chronic PEO] developing in later adulthood). Other rarer phenotypes are Kearns-Sayre syndrome (KSS) and mitochondrial neurogastrointestinal encephalopathy (MNGIE).","content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"24741716\",\"@Source\":\"PubMed\"},{\"$\":\"NBK195854\",\"@Source\":\"BookShelf\"}]}}","alternate_names":["MITOCHONDRIAL DNA DEPLETION SYNDROME 8A (ENCEPHALOMYOPATHIC TYPE WITH RENAL TUBULOPATHY)","MITOCHONDRIAL DNA DEPLETION SYNDROME, ENCEPHALOMYOPATHIC, WITH RENAL TUBULOPATHY, AUTOSOMAL RECESSIVE","RRM2B-Related Mitochondrial DNA Depletion Syndrome, Encephalomyopathic Form, with Renal Tubulopathy"],"attribute_content":[]}
{"type":"Disease","keywords":["hereditary cancer syndrome"],"medgen_id":"C3839822","id":"13889","name":"DICER1-related pleuropulmonary blastoma cancer predisposition syndrome","alternate_symbols":[],"symbol":"PPBFTDS","gard_id":"10734","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0017288\"}","{\"db\":\"OMIM\",\"id\":\"601200\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"284343\"}","{\"db\":\"OMIM\",\"id\":\"601200\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"PPB FAMILIAL TUMOR AND DYSPLASIA SYNDROME\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"10734\",\"ref_field\":\"gard_id\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK196157\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"601200\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"public_definition":"DICER1 tumor predisposition (DICER1) is characterized by an increased risk for pleuropulmonary blastoma (PPB), pulmonary cysts, thyroid gland neoplasia (multinodular goiter, adenomas, and/or thyroid cancer), ovarian tumors (Sertoli-Leydig cell tumor, gynandroblastoma, and sarcoma), and cystic nephroma. Less commonly observed tumors include ciliary body medulloepithelioma, nasal chondromesenchymal hamartoma, embryonal rhabdomyosarcoma, pituitary blastoma, pineoblastoma, central nervous system (CNS) sarcoma, other CNS tumors, and presacral malignant teratoid tumor. The majority of tumors occur in individuals younger than age 40 years. PPB typically presents in infants and children younger than age six years. Ovarian sex cord-stromal tumors are most often diagnosed before age 40 years. Cystic nephroma generally presents in young children but has also been reported in adolescents. Additional clinical features that may be seen include macrocephaly, ocular abnormalities, structural anomalies of the kidney and collecting system, and dental anomalies (bulbous crowns).","content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"24761742\",\"@Source\":\"PubMed\"},{\"$\":\"NBK196157\",\"@Source\":\"BookShelf\"}]}}","alternate_names":["DICER1 syndrome","PPB FAMILIAL TUMOR AND DYSPLASIA SYNDROME"],"attribute_content":[]}
{"type":"Disease","keywords":[],"medgen_id":"C0878684","id":"5913","name":"SHORT syndrome","alternate_symbols":[],"gard_id":"7633","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0010026\"}","{\"db\":\"OMIM\",\"id\":\"269880\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"3163\"}","{\"db\":\"OMIM\",\"id\":\"269880\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"LIPODYSTROPHY, PARTIAL, WITH RIEGER ANOMALY AND SHORT STATURE\"}","{\"db\":\"OMIM\",\"id\":\"269880\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"SHORT STATURE, HYPEREXTENSIBILITY, HERNIA, OCULAR DEPRESSION, RIEGER ANOMALY, AND TEETHING DELAY\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"7633\",\"ref_field\":\"gard_id\"}","{\"db\":\"Genetic Alliance\",\"id\":\"SHORT+syndrome/6576\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK201365\",\"ref_field\":\"public_definition\"}"],"public_definition":"SHORT syndrome is a mnemonic for short stature, hyperextensibility, ocular depression (deeply set eyes), Rieger anomaly, and teething delay. It is now recognized that the features most consistently observed in SHORT syndrome are mild intrauterine growth restriction (IUGR); mild to moderate short stature; partial lipodystrophy (evident in the face, and later in the chest and upper extremities, often sparing the buttocks and legs); and a characteristic facial gestalt. Insulin resistance may be evident in mid-childhood or adolescence, although diabetes mellitus typically does not develop until early adulthood. Other frequent features include Axenfeld-Rieger anomaly or related ocular anterior chamber dysgenesis, delayed dentition and other dental issues, and sensorineural hearing loss.","content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"24830046\",\"@Source\":\"PubMed\"},{\"$\":\"NBK201365\",\"@Source\":\"BookShelf\"}]}}","alternate_names":["LIPODYSTROPHY, PARTIAL, WITH RIEGER ANOMALY AND SHORT STATURE","SHORT STATURE, HYPEREXTENSIBILITY, HERNIA, OCULAR DEPRESSION, RIEGER ANOMALY, AND TEETHING DELAY","Stature, Hyperextensibility of joints or Hernia (inguinal), Ocular depression, Rieger anomaly and Teething delay"],"attribute_content":[]}
{"type":"Disease","keywords":[],"medgen_id":"C3149276","id":"15825","name":"Chromosome 16p12.1 deletion syndrome, 520kb","alternate_symbols":[],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0007631\"}","{\"db\":\"OMIM\",\"id\":\"136570\",\"type\":\"MIM\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0007631\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK274565\",\"ref_field\":\"public_definition\"}"],"public_definition":"16p12.2 recurrent deletion is characterized by variable clinical findings that do not constitute a recognizable syndrome. Of note, the significant bias in ascertainment of individuals undergoing clinical chromosomal microarray analysis (i.e., children with intellectual disability and developmental delay; individuals with schizophrenia) makes it difficult to accurately associate specific phenotypes with the 16p12.2 recurrent deletion. Findings commonly observed in children (probands) with this deletion include: developmental delay, cognitive impairment (ranging from mild to profound), growth impairment (including short stature), cardiac malformations, epilepsy, and psychiatric and/or behavioral problems. Other findings can include: hearing loss, dental abnormalities, renal and genital anomalies (the latter in males), and cleft palate ± cleft lip.","content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"25719193\",\"@Source\":\"PubMed\"},{\"$\":\"NBK274565\",\"@Source\":\"BookShelf\"}]}}","alternate_names":["16p12.2 Microdeletion","Chromosome 16p12.1 deletion syndrome, 520-kb"],"attribute_content":[]}
{"type":"Disease","keywords":[],"medgen_id":"C3810404","id":"18709","name":"Carbonic anhydrase VA deficiency, hyperammonemia due to","alternate_symbols":[],"symbol":"CA5AD","gard_id":"13201","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0014332\"}","{\"db\":\"OMIM\",\"id\":\"615751\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"401948\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"13201\",\"ref_field\":\"gard_id\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK284774\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"615751\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"public_definition":"The four children with carbonic anhydrase VA (CA-VA) deficiency reported to date presented between day two of life and age 20 months with hyperammonemic encephalopathy (i.e., lethargy, feeding intolerance, weight loss, tachypnea, seizures, and coma). Data on long-term follow up are limited (the oldest known patient is age 7 years). Two of the four children showed normal psychomotor development and two showed mild learning difficulties and delayed motor skills. Seven additional children diagnosed with CA-VA deficiency (but not yet published) presented similarly.","content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"25834911\",\"@Source\":\"PubMed\"},{\"$\":\"NBK284774\",\"@Source\":\"BookShelf\"}]}}","alternate_names":[],"attribute_content":[]}
{"type":"Disease","keywords":[],"medgen_id":"C2675526","id":"3466","name":"Severe congenital neutropenia 4, autosomal recessive","alternate_symbols":[],"symbol":"SCN4","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0012930\"}","{\"db\":\"OMIM\",\"id\":\"612541\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"331176\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Neutropenia%2C+severe+congenital%2C+4%2C+autosomal+recessive/9006\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK285321\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"612541\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"public_definition":"G6PC3 deficiency is characterized by severe congenital neutropenia which occurs in a phenotypic continuum that includes the following: Isolated severe congenital neutropenia (nonsyndromic). Classic G6PC3 deficiency (severe congenital neutropenia plus cardiovascular and/or urogenital abnormalities). Severe G6PC3 deficiency (classic G6PC3 deficiency plus involvement of non-myeloid hematopoietic cell lines, additional extra-hematologic features, and pulmonary hypertension; known as Dursun syndrome). Neutropenia usually presents with recurrent bacterial infections in the first few months of life. Intrauterine growth restriction (IUGR), failure to thrive (FTT), and poor postnatal growth are common. Other findings in classic and severe G6PC3 deficiency can include inflammatory bowel disease (IBD) resembling Crohn's disease, and endocrine disorders (growth hormone deficiency, hypogonadotropic hypogonadism, and delayed puberty).","content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"25879134\",\"@Source\":\"PubMed\"},{\"$\":\"NBK285321\",\"@Source\":\"BookShelf\"}]}}","alternate_names":[],"attribute_content":[]}
{"type":"Disease","keywords":[],"medgen_id":"C3554398","id":"17579","name":"Spinal muscular atrophy, jokela type","alternate_symbols":[],"symbol":"SMAJ","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0014025\"}","{\"db\":\"OMIM\",\"id\":\"615048\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"276435\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK304142\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"615048\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"public_definition":"CHCHD10-related disorders are characterized by a spectrum of adult-onset neurologic findings that can include: Mitochondrial myopathy (may also be early-onset): weakness, amyotrophy, exercise intolerance. Amyotrophic lateral sclerosis (ALS): progressive degeneration of upper motor neurons (UMNs) and lower motor neurons (LMNs). Frontotemporal dementia (FTD): slowly progressive behavioral changes, language disturbances, cognitive decline, extrapyramidal signs. Late-onset spinal motor neuronopathy (SMAJ): weakness, cramps, and/or fasciculations; areflexia. Cerebellar ataxia: gait ataxia, kinetic ataxia (progressive loss of coordination of lower- and upper-limb movements), dysarthria/dysphagia, nystagmus, cerebellar oculomotor disorder. Because of the recent discovery of CHCHD10-related disorders and the limited number of affected individuals reported to date, the natural history of these disorders (except for SMAJ caused by the p.Gly66Val pathogenic variant) is largely unknown.","content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"26131548\",\"@Source\":\"PubMed\"},{\"$\":\"NBK304142\",\"@Source\":\"BookShelf\"}]}}","alternate_names":[],"attribute_content":[]}
{"type":"Disease","keywords":[],"medgen_id":"C2675336","id":"903","name":"Chromosome 15q11-q13 duplication syndrome","alternate_symbols":[],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0012081\"}","{\"db\":\"OMIM\",\"id\":\"608636\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"238446\"}","{\"db\":\"OMIM\",\"id\":\"608636\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DUPLICATION 15q11-q13 SYNDROME\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK367946\",\"ref_field\":\"public_definition\"}"],"public_definition":"15q duplication syndrome and related disorders (dup15q) are caused by presence of at least one extra maternally derived copy of the Prader-Willi/Angelman critical region (PWACR) within chromosome 15q11.2-q13.1. The extra copy or copies most commonly arise by one of two mechanisms: A maternal isodicentric 15q11.2-q13.1 supernumerary chromosome – idic(15) – typically comprising two extra copies of 15q11.2-q13.1 and resulting in tetrasomy for 15q11.2-q13.1 (~80% of cases); A maternal interstitial 15q11.2-q13.1 duplication that typically includes one extra copy of 15q11.2-q13.1 within chromosome 15, resulting in trisomy for 15q11.2-q13.1 (~20% of cases). Dup15q is characterized by hypotonia and motor delays, intellectual disability, autism spectrum disorder (ASD), and epilepsy including infantile spasms. Rarely, dup15q may also be associated with psychosis or sudden unexplained death. Those with maternal idic(15) are typically more severely affected than those with an interstitial duplication.","content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"27308687\",\"@Source\":\"PubMed\"},{\"$\":\"NBK367946\",\"@Source\":\"BookShelf\"}]}}","alternate_names":["15q11.2-q13.1 Duplication Syndrome","DUPLICATION 15q11-q13 SYNDROME"],"attribute_content":[]}
{"type":"Disease","keywords":[],"medgen_id":"C3553349","id":"16993","name":"Coenzyme Q10 deficiency, primary, 6","alternate_symbols":[],"symbol":"COQ10D6","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0013836\"}","{\"db\":\"OMIM\",\"id\":\"614650\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"280406\"}","{\"db\":\"Genetic Alliance\",\"id\":\"COENZYME+Q10+DEFICIENCY%2C+PRIMARY%2C+6/7997\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK410087\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"614650\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"public_definition":"Primary coenzyme Q10 (CoQ10) deficiency is usually associated with multisystem involvement, including neurologic manifestations such as fatal neonatal encephalopathy with hypotonia; a late-onset slowly progressive multiple-system atrophy-like phenotype (neurodegeneration with autonomic failure and various combinations of parkinsonism and cerebellar ataxia, and pyramidal dysfunction); and dystonia, spasticity, seizures, and intellectual disability. Steroid-resistant nephrotic syndrome (SRNS), the hallmark renal manifestation, is often the initial manifestation either as isolated renal involvement that progresses to end-stage renal disease (ESRD), or associated with encephalopathy (seizures, stroke-like episodes, severe neurologic impairment) resulting in early death. Hypertrophic cardiomyopathy (HCM), retinopathy or optic atrophy, and sensorineural hearing loss can also be seen.","content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"28125198\",\"@Source\":\"PubMed\"},{\"$\":\"NBK410087\",\"@Source\":\"BookShelf\"}]}}","alternate_names":[],"attribute_content":[]}
{"type":"Disease","keywords":[],"medgen_id":"C1864100","id":"4057","name":"Pseudohypoparathyroidism type 1B","alternate_symbols":[],"symbol":"PHP1B","gard_id":"10680","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0011301\"}","{\"db\":\"OMIM\",\"id\":\"603233\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"94089\"}","{\"db\":\"OMIM\",\"id\":\"603233\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"PHP IB\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"10680\",\"ref_field\":\"gard_id\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Pseudohypoparathyroidism+type+1B/6036\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK459117\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"603233\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"public_definition":"Disorders of GNAS inactivation include the phenotypes pseudohypoparathyroidism Ia, Ib, and Ic (PHP-Ia, -Ib, -Ic), pseudopseudohypoparathyroidism (PPHP), progressive osseous heteroplasia (POH), and osteoma cutis (OC). PHP-Ia and PHP-Ic are characterized by: End-organ resistance to endocrine hormones including parathyroid hormone (PTH), thyroid-stimulating hormone (TSH), gonadotropins (LH and FSH), growth hormone-releasing hormone (GHRH), and CNS neurotransmitters (leading to obesity and variable degrees of intellectual disability and developmental delay); and The Albright hereditary osteodystrophy (AHO) phenotype (short stature, round facies, and subcutaneous ossifications) and brachydactyly type E (shortening mainly of the 4th and/or 5th metacarpals and metatarsals and distal phalanx of the thumb). Although PHP-Ib is characterized principally by PTH resistance, some individuals also have partial TSH resistance and mild features of AHO (e.g., brachydactyly). PPHP, a more limited form of PHP-Ia, is characterized by various manifestations of the AHO phenotype without the hormone resistance or obesity. POH and OC are even more restricted variants of PPHP: POH consists of dermal ossification beginning in infancy, followed by increasing and extensive bone formation in deep muscle and fascia. OC consists of extra-skeletal ossification that is limited to the dermis and subcutaneous tissues.","content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"29072892\",\"@Source\":\"PubMed\"},{\"$\":\"NBK459117\",\"@Source\":\"BookShelf\"}]}}","alternate_names":["PHP IB","Pseudohypoparathyroidism Type IB"],"attribute_content":[]}
{"type":"Disease","keywords":[],"medgen_id":"C3554168","id":"17497","name":"Combined oxidative phosphorylation deficiency 14","alternate_symbols":[],"symbol":"COXPD14","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0013986\"}","{\"db\":\"OMIM\",\"id\":\"614946\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"319519\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK538658\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"614946\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"public_definition":"The spectrum of FARS2 deficiency ranges from the infantile-onset phenotype, characterized by epileptic encephalopathy with lactic acidosis and poor prognosis (70% of affected individuals), to the later-onset phenotype, characterized by spastic paraplegia, less severe neurologic manifestations, and longer survival (30% of affected individuals). To date FARS2 deficiency has been reported in 37 individuals from 25 families. Infantile-onset phenotype. Seizures are difficult to control and may progress quickly at an early age to intractable seizures with frequent status epilepticus; some children have hypsarrhythmia on EEG. All have developmental delay; most are nonverbal and unable to walk. Feeding difficulties are common. More than half of affected children die in early childhood. Later-onset phenotype. All affected individuals have spastic paraplegia manifested by weakness, spasticity, and exaggerated reflexes of the lower extremities associated with walking difficulties; some have developmental delay/intellectual disability; some have brief seizures that resolve over time.","content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"30869852\",\"@Source\":\"PubMed\"},{\"$\":\"NBK538658\",\"@Source\":\"BookShelf\"}]}}","alternate_names":[],"attribute_content":[]}
{"type":"Disease","keywords":["Hereditary cancer syndrome","Neoplasm"],"medgen_id":"C1321489","id":"3222","name":"Muir-Torré syndrome","disease_mechanism":"loss of function","alternate_symbols":[],"symbol":"MRTES","gard_id":"6821","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0008018\"}","{\"db\":\"OMIM\",\"id\":\"158320\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"587\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0008018\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Muir-Torre syndrome\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000501399\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000501401\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000514728\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000514729\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000515534\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000518997\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000520069\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000527981\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000527984\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000528339\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000528529\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000528914\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000528915\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000528930\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000529017\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000530120\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000530202\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000556509\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000569423\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"6821\",\"ref_field\":\"gard_id\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Keratoacanthoma/3972\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"403824007\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1211\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"158320\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"disease_mechanism_id":"273","public_definition":"Lynch syndrome is characterized by an increased risk for colorectal cancer (CRC) and cancers of the endometrium, stomach, ovary, small bowel, hepatobiliary tract, urinary tract, brain, and skin. In individuals with Lynch syndrome the following lifetime risks for cancer are seen: CRC: 52%-82% (mean age at diagnosis 44-61 years). Endometrial cancer in females: 25%-60% (mean age at diagnosis 48-62 years). Gastric cancer: 6%-13% (mean age at diagnosis 56 years). Ovarian cancer: 4%-12% (mean age at diagnosis 42.5 years; ~30% are diagnosed \u003c age 40 years). The risk for other Lynch syndrome-related cancers is lower, though substantially increased over general population rates.","content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301390\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1211\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"EGAPP, 2009\",\"@Type\":\"Position Statement\",\"ID\":{\"$\":\"2743612\",\"@Source\":\"pmc\"}},{\"@Abbrev\":\"Ponti, 2005\",\"@Type\":\"review\",\"ID\":{\"$\":\"15662714\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ASCRS, 2001\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"11598466\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"NSGC, 2004\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"15604628\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"NSGC/CCA-ICC, 2012\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"22167527\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"SGO, 2014\",\"@Type\":\"practice guideline\",\"CitationText\":{\"$\":\"Society of Gynecologic Oncology (SGO) Clinical Practice Statement: Screening for Lynch Syndrome in Endometrial Cancer\"},\"URL\":{\"$\":\"https://www.sgo.org/clinical-practice/guidelines/screening-for-lynch-syndrome-in-endometrial-cancer\"}}]}","alternate_names":["Cutaneous sebaceous neoplasms and keratoacanthomas multiple with gastrointestinal and other carcinomas","MLH1-Related Muir-Torre Syndrome","MSH2-Related Muir-Torre Syndrome","Muir-Torre syndrome"],"attribute_content":[]}
{"type":"Disease","keywords":[],"medgen_id":"CN043651","id":"9547","name":"Deafness, X-linked","alternate_symbols":[],"symbol":"DFNX","gard_id":"1715","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0019586\"}","{\"db\":\"OMIM\",\"id\":\"PS304500\",\"type\":\"Phenotypic series\"}","{\"db\":\"Orphanet\",\"id\":\"90625\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"1715\",\"ref_field\":\"gard_id\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Deafness%2C+X-Linked%2C+DFN/2162\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"PS304500\",\"type\":\"Phenotypic series\",\"ref_field\":\"name\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"nonsyndromic-hearing-loss\",\"ref_field\":\"public_definition\"}"],"public_definition":"Nonsyndromic hearing loss is a partial or total loss of hearing that is not associated with other signs and symptoms. In contrast, syndromic hearing loss occurs with signs and symptoms affecting other parts of the body.Nonsyndromic hearing loss can be classified in several different ways. One common way is by the condition's pattern of inheritance: autosomal dominant (DFNA), autosomal recessive (DFNB), X-linked (DFNX), or mitochondrial (which does not have a special designation). Each of these types of hearing loss includes multiple subtypes. DFNA, DFNB, and DFNX subtypes are numbered in the order in which they were first described. For example, DFNA1 was the first type of autosomal dominant nonsyndromic hearing loss to be identified.The characteristics of nonsyndromic hearing loss vary among the different types. Hearing loss can affect one ear (unilateral) or both ears (bilateral). Degrees of hearing loss range from mild (difficulty understanding soft speech) to profound (inability to hear even very loud noises). The term \"deafness\" is often used to describe severe-to-profound hearing loss. Hearing loss can be stable, or it may be progressive, becoming more severe as a person gets older. Particular types of nonsyndromic hearing loss show distinctive patterns of hearing loss. For example, the loss may be more pronounced at high, middle, or low tones.Most forms of nonsyndromic hearing loss are described as sensorineural, which means they are associated with a permanent loss of hearing caused by damage to structures in the inner ear. The inner ear processes sound and sends the information to the brain in the form of electrical nerve impulses. Less commonly, nonsyndromic hearing loss is described as conductive, meaning it results from changes in the middle ear. The middle ear contains three tiny bones that help transfer sound from the eardrum to the inner ear. Some forms of nonsyndromic hearing loss, particularly a type called DFNX2, involve changes in both the inner ear and the middle ear. This combination is called mixed hearing loss.Depending on the type, nonsyndromic hearing loss can become apparent at any time from infancy to old age. Hearing loss that is present before a child learns to speak is classified as prelingual or congenital. Hearing loss that occurs after the development of speech is classified as postlingual.","content":"{\"Citation\":[{\"@Abbrev\":\"ACMG, 2002\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"3110944\",\"@Source\":\"pmc\"}},{\"@Abbrev\":\"ACMG, 2014\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"24651602\",\"@Source\":\"PubMed\"}}]}","alternate_names":[],"attribute_content":[]}
{"type":"Disease","keywords":[],"medgen_id":"C1834570","id":"3138","name":"Myoclonic dystonia","alternate_symbols":[],"symbol":"DYT11","xrefs":["{\"db\":\"OMIM\",\"id\":\"159900\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"36899\"}","{\"db\":\"OMIM\",\"id\":\"159900\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DYSTONIA 11, MYOCLONIC\"}","{\"db\":\"OMIM\",\"id\":\"604149.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DYSTONIA 11, MYOCLONIC\"}","{\"db\":\"OMIM\",\"id\":\"604149.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DYSTONIA 11, MYOCLONIC\"}","{\"db\":\"OMIM\",\"id\":\"604149.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DYSTONIA 11, MYOCLONIC\"}","{\"db\":\"OMIM\",\"id\":\"604149.0004\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DYSTONIA 11, MYOCLONIC\"}","{\"db\":\"OMIM\",\"id\":\"604149.0005\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DYSTONIA 11, MYOCLONIC\"}","{\"db\":\"OMIM\",\"id\":\"604149.0006\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DYSTONIA 11, MYOCLONIC\"}","{\"db\":\"OMIM\",\"id\":\"604149.0007\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DYSTONIA 11, MYOCLONIC\"}","{\"db\":\"OMIM\",\"id\":\"604149.0008\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DYSTONIA 11, MYOCLONIC\"}","{\"db\":\"OMIM\",\"id\":\"604149.0009\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DYSTONIA 11, MYOCLONIC\"}","{\"db\":\"OMIM\",\"id\":\"604149.0010\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DYSTONIA 11, MYOCLONIC\"}","{\"db\":\"OMIM\",\"id\":\"604149.0011\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DYSTONIA 11, MYOCLONIC\"}","{\"db\":\"OMIM\",\"id\":\"604149.0012\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DYSTONIA 11, MYOCLONIC\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Dystonia+11/2408\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"439732004\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1414\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"159900\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"public_definition":"SGCE myoclonus-dystonia (SGCE-M-D) is a movement disorder characterized by a combination of rapid, brief muscle contractions (myoclonus) and/or sustained twisting and repetitive movements that result in abnormal postures (dystonia). The myoclonic jerks typical of SGCE-M-D most often affect the neck, trunk, and upper limbs with less common involvement of the legs. Approximately 50% of affected individuals have additional focal or segmental dystonia, presenting as cervical dystonia and/or writer's cramp. Non-motor features may include alcohol abuse, obsessive-compulsive disorder (OCD), and anxiety disorders. Symptom onset is usually in the first decade of life and almost always by age 20 years, but ranges from age six months to 80 years. Most affected adults report a dramatic reduction in myoclonus in response to alcohol ingestion. SGCE-M-D is compatible with an active life of normal span.","content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301587\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1414\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"EFNS, 2011\",\"@Type\":\"Recommendation\",\"ID\":{\"$\":\"20482602\",\"@Source\":\"PubMed\"}}]}","alternate_names":["DYSTONIA 11, MYOCLONIC","DYT-SGCE","Dystonia 11","Dystonia, alcohol responsive","Hereditary essential myoclonus","Myoclonus-Dystonia","Myoclonus-dystonia syndrome"],"attribute_content":[]}
{"type":"Disease","keywords":[],"medgen_id":"C0751651","id":"9530","name":"Mitochondrial diseases","alternate_symbols":[],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0044970\"}","{\"db\":\"Orphanet\",\"id\":\"68380\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Mitochondrial+Disorders/4830\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1224\",\"ref_field\":\"public_definition\"}"],"public_definition":"Mitochondrial diseases are a clinically heterogeneous group of disorders that arise as a result of dysfunction of the mitochondrial respiratory chain. They can be caused by mutation of genes encoded by either nuclear DNA or mitochondrial DNA (mtDNA). While some mitochondrial disorders only affect a single organ (e.g., the eye in Leber hereditary optic neuropathy [LHON]), many involve multiple organ systems and often present with prominent neurologic and myopathic features. Mitochondrial disorders may present at any age. Many individuals with a mutation of mtDNA display a cluster of clinical features that fall into a discrete clinical syndrome, such as the Kearns-Sayre syndrome (KSS), chronic progressive external ophthalmoplegia (CPEO), mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes (MELAS), myoclonic epilepsy with ragged-red fibers (MERRF), neurogenic weakness with ataxia and retinitis pigmentosa (NARP), or Leigh syndrome (LS). However, considerable clinical variability exists and many individuals do not fit neatly into one particular category, which is well-illustrated by the overlapping spectrum of disease phenotypes (including mitochondrial recessive ataxia syndrome (MIRAS) resulting from mutation of the nuclear gene POLG, which has emerged as a major cause of mitochondrial disease. Common clinical features of mitochondrial disease – whether involving a mitochondrial or nuclear gene – include ptosis, external ophthalmoplegia, proximal myopathy and exercise intolerance, cardiomyopathy, sensorineural deafness, optic atrophy, pigmentary retinopathy, and diabetes mellitus. Common central nervous system findings are fluctuating encephalopathy, seizures, dementia, migraine, stroke-like episodes, ataxia, and spasticity. A high incidence of mid- and late pregnancy loss is a common occurrence that often goes unrecognized.","content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301403\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1224\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"MMS, 2014\",\"@Type\":\"Position Statement\",\"ID\":{\"$\":\"25503498\",\"@Source\":\"PubMed\"}}]}","alternate_names":["Mitochondrial disease"],"attribute_content":[]}
{"type":"Disease","keywords":[],"medgen_id":"C0270972","id":"16501","name":"De Lange syndrome","alternate_symbols":[],"symbol":"CDLS","gard_id":"10109","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0016033\"}","{\"db\":\"OMIM\",\"id\":\"PS122470\",\"type\":\"Phenotypic series\"}","{\"db\":\"Orphanet\",\"id\":\"199\"}","{\"db\":\"OMIM\",\"id\":\"122470\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CDL\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"cornelia-de-lange-syndrome\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Cornelia de Lange syndrome\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0016033\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Cornelia de Lange syndrome\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"10109\",\"ref_field\":\"gard_id\"}","{\"db\":\"SNOMED CT\",\"id\":\"40354009\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1104\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"122470\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"public_definition":"Classic Cornelia de Lange syndrome (CdLS) is characterized by distinctive facial features, growth retardation (prenatal onset; \u003c5th centile throughout life), hirsutism, and upper-limb reduction defects that range from subtle phalangeal abnormalities to oligodactyly (missing digits). Craniofacial features include synophrys, highly arched eyebrows, long eyelashes, short nose with anteverted nares, small widely spaced teeth, and microcephaly. IQ ranges from below 30 to 102 (mean: 53). Many individuals demonstrate autistic and self-destructive tendencies. Frequent findings include cardiac septal defects, gastrointestinal dysfunction, hearing loss, myopia, and cryptorchidism or hypoplastic genitalia. Individuals with a milder phenotype have less severe growth, cognitive, and limb involvement, but often have facial features consistent with CdLS.","content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301283\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1104\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"ACMG, 2013\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"23519317\",\"@Source\":\"PubMed\"}}]}","alternate_names":["CDL","Cornelia de Lange syndrome"],"attribute_content":[]}
{"type":"Disease","keywords":[],"medgen_id":"C1867450","id":"3553","name":"Pseudoxanthoma elasticum, forme fruste","alternate_symbols":[],"gard_id":"10104","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0008333\"}","{\"db\":\"OMIM\",\"id\":\"177850\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"758\"}","{\"db\":\"OMIM\",\"id\":\"177850\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"PSEUDOXANTHOMA ELASTICUM, HETEROZYGOUS\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"10104\",\"ref_field\":\"gard_id\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Pseudoxanthoma+elasticum%2C+forme+fruste/6056\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1113\",\"ref_field\":\"public_definition\"}"],"public_definition":"Pseudoxanthoma elasticum (PXE) is a systemic disorder that affects the elastic tissue of the skin, the eye, and vascular system. Individuals most commonly present with angioid streaks of the retina found on routine eye examination or associated with retinal hemorrhage and/or characteristic papules in the skin. The most frequent cause of morbidity and disability in PXE is reduced vision due to complications of subretinal neovascularizations and macular atrophy. Other manifestations include premature gastrointestinal angina and/or bleeding, intermittent claudication of arm and leg muscles, stroke, renovascular hypertension, and cardiovascular complications (angina/myocardial infarction). Most affected individuals live a normal life span.","content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301292\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1113\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"Uitto et al., 2012\",\"@Type\":\"Suggested Reading\",\"ID\":{\"$\":\"3121926\",\"@Source\":\"pmc\"}}]}","alternate_names":["PSEUDOXANTHOMA ELASTICUM, HETEROZYGOUS","Pseudoxanthoma Elasticum, Incomplete"],"attribute_content":["{\"Attribute\":{\"$\":\"Excluding this from the dictionary per request from Sharon Terry.\",\"@Type\":\"exclude from dictionary\"}}"]}
{"type":"Disease","keywords":[],"medgen_id":"C0033847","id":"3552","name":"Pseudoxanthoma elasticum","alternate_symbols":[],"symbol":"PXE","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0009925\"}","{\"db\":\"OMIM\",\"id\":\"264800\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"758\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Pseudoxanthoma+elasticum/6053\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"252246005\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1113\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"264800\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"public_definition":"Pseudoxanthoma elasticum (PXE) is a systemic disorder that affects the elastic tissue of the skin, the eye, and vascular system. Individuals most commonly present with angioid streaks of the retina found on routine eye examination or associated with retinal hemorrhage and/or characteristic papules in the skin. The most frequent cause of morbidity and disability in PXE is reduced vision due to complications of subretinal neovascularizations and macular atrophy. Other manifestations include premature gastrointestinal angina and/or bleeding, intermittent claudication of arm and leg muscles, stroke, renovascular hypertension, and cardiovascular complications (angina/myocardial infarction). Most affected individuals live a normal life span.","content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301292\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1113\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"Uitto et al., 2012\",\"@Type\":\"Suggested Reading\",\"ID\":{\"$\":\"3121926\",\"@Source\":\"pmc\"}}]}","alternate_names":["Gronblad Strandberg syndrome"],"attribute_content":[]}
{"type":"Disease","keywords":[],"medgen_id":"C1857728","id":"4586","name":"Hereditary angioedema type 3","alternate_symbols":[],"symbol":"HAE3","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0012526\"}","{\"db\":\"OMIM\",\"id\":\"610618\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"100054\"}","{\"db\":\"OMIM\",\"id\":\"610618\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"ESTROGEN-RELATED HAE\"}","{\"db\":\"OMIM\",\"id\":\"610618\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"ESTROGEN-SENSITIVE HAE\"}","{\"db\":\"OMIM\",\"id\":\"610618\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HAE III\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Hereditary+angioedema%2C+type+III/8512\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Hereditary angioedema, type III\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0012526\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"610618\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"content":"{\"Citation\":{\"@Abbrev\":\"Orphanet, 2009\",\"@Type\":\"practice guideline\",\"CitationText\":{\"$\":\"Orphanet, Non histamine-induced angioedema, 2009\"},\"URL\":{\"$\":\"https://www.orpha.net/data/patho/Pro/en/Emergency_NonHistamineInducedAngioedema.pdf\"}}}","alternate_names":["ESTROGEN-RELATED HAE","ESTROGEN-SENSITIVE HAE","HAE III","Hereditary angioedema, type III"],"attribute_content":[]}
{"type":"Disease","keywords":[],"medgen_id":"C3495591","id":"4778","name":"Charcot-Marie-Tooth disease and deafness","alternate_symbols":[],"symbol":"CMT1E","gard_id":"9190","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0007311\"}","{\"db\":\"OMIM\",\"id\":\"118300\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"90658\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Charcot-Marie-Tooth+Disease+Type+1E/1288\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Charcot-Marie-Tooth disease, type 1E\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"9190\",\"ref_field\":\"gard_id\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"charcot-marie-tooth-disease\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"118300\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"public_definition":"Charcot-Marie-Tooth disease encompasses a group of disorders called hereditary sensory and motor neuropathies that damage the peripheral nerves. Peripheral nerves connect the brain and spinal cord to muscles and to sensory cells that detect sensations such as touch, pain, heat, and sound. Damage to the peripheral nerves that worsens over time can result in alteration or loss of sensation and wasting (atrophy) of muscles in the feet, legs, and hands.Charcot-Marie-Tooth disease usually becomes apparent in adolescence or early adulthood, but onset may occur anytime from early childhood through late adulthood. Symptoms of Charcot-Marie-Tooth disease vary in severity and age of onset even among members of the same family. Some people never realize they have the disorder because their symptoms are so mild, but most have a moderate amount of physical disability. A small percentage of people experience severe weakness or other problems which, in very rare cases, can be life-threatening. In most affected individuals, however, Charcot-Marie-Tooth disease does not affect life expectancy.Typically, the earliest symptoms of Charcot-Marie-Tooth disease result from muscle atrophy in the feet. Affected individuals may have foot abnormalities such as high arches (pes cavus), flat feet (pes planus), or curled toes (hammer toes). They often have difficulty flexing the foot or walking on the heel of the foot. These difficulties may cause a higher than normal step (steppage gait) and increase the risk of ankle injuries and tripping. As the disease worsens, muscles in the lower legs usually weaken, but leg and foot problems rarely require the use of a wheelchair.Affected individuals may also develop weakness in the hands, causing difficulty with daily activities such as writing, fastening buttons, and turning doorknobs. People with Charcot-Marie-Tooth disease typically experience a decreased sensitivity to touch, heat, and cold in the feet and lower legs, but occasionally feel aching or burning sensations. In rare cases, affected individuals have loss of vision or gradual hearing loss that sometimes leads to deafness.There are several types of Charcot-Marie-Tooth disease, which are differentiated by their effects on nerve cells and patterns of inheritance. Type 1 (CMT1) is characterized by abnormalities in myelin, the fatty substance that covers nerve cells, protecting them and helping to transmit nerve impulses. These abnormalities slow the transmission of nerve impulses and can affect the health of the nerve fiber. Type 2 (CMT2) is characterized by abnormalities in the fiber, or axon, that extends from a nerve cell body to muscles or to sense organs. These abnormalities reduce the strength of the nerve impulse. In forms of Charcot-Marie-Tooth disease classified as intermediate type, the nerve impulses are both slowed and reduced in strength, probably due to abnormalities in both myelin and axons. Type 4 (CMT4) is distinguished from the other types by its pattern of inheritance; it can affect either the axons or the myelin. Type X Charcot-Marie-Tooth disease (CMTX) is caused by mutations in genes on the X chromosome, one of the two sex chromosomes. Within the various types of Charcot-Marie-Tooth disease, subtypes (such as CMT1A, CMT1B, CMT2A, CMT4A, and CMTX1) indicate different genetic causes.Sometimes other, historical names are used to refer to particular forms of Charcot-Marie-Tooth disease. For example, Roussy-Levy syndrome is a form of CMT11 with the additional feature of rhythmic shaking (tremors). Dejerine-Sottas syndrome is a term sometimes used to describe a severe, early childhood form of Charcot-Marie-Tooth disease; it is also sometimes called type 3 (CMT3). Depending on the specific gene that is altered, this severe, early-onset form of the disorder may also be classified as CMT1 or CMT4. CMTX5 is also known as Rosenberg-Chutorian syndrome.","content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301384\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1205\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"MDA Consensus document - CMT testing, 2011\",\"@Type\":\"general\",\"ID\":{\"$\":\"3058597\",\"@Source\":\"pmc\"}}]}","alternate_names":["CMT 1E","Charcot-Marie-Tooth Neuropathy Type 1E","Charcot-Marie-Tooth disease, demyelinating, Type 1E","Charcot-Marie-Tooth disease, type 1E","Charcot-Marie-Tooth neuropathy and deafness, autosomal dominant"],"attribute_content":[]}
{"type":"Disease","keywords":[],"medgen_id":"C2675556","id":"1591","name":"Encephalopathy, acute, infection-induced, 3, suceptibility to","alternate_symbols":["ANE"],"symbol":"IIAE3","gard_id":"13232","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0011953\"}","{\"db\":\"OMIM\",\"id\":\"608033\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"88619\"}","{\"db\":\"OMIM\",\"id\":\"608033\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"ENCEPHALOPATHY, ACUTE NECROTIZING, SUSCEPTIBILITY TO\"}","{\"db\":\"OMIM\",\"id\":\"608033\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"ANE\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"13232\",\"ref_field\":\"gard_id\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Encephalopathy%2C+acute%2C+infection-induced%2C+3%2C+suceptibility+to/8307\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK258641\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"608033\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"public_definition":"Infection-induced acute encephalopathy 3 (IIAE3) is the susceptibility to recurrent acute necrotizing encephalopathy (ANE) caused by a heterozygous pathogenic variant in RANBP2. ANE refers to the specific neurologic presentation in which bilateral symmetric thalamic, midbrain, and/or hindbrain lesions occur within days following the onset of an acute viral illness caused by influenza A, influenza B, parainfluenza II, human herpes virus 6, coxsackie virus, or an enterovirus. Although most IIAE3 occurs before age six years, first episodes have been observed in teenagers and adults. ANE begins within 12 hours to three or four days of the first awareness of viral symptoms (fever, cough, rhinorrhea, vomiting, diarrhea, and malaise). The most common sign of ANE is lethargy that progresses to coma (which may last for weeks) and seizures (in 50%). One third of affected individuals die during the acute phase of the encephalopathy; of the survivors, one half have permanent neurologic damage and the remainder have no discernible residual symptoms. Fifty per cent of persons with IIAE3 will have at least one repeat episode and some will have multiple repeat episodes","content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"25473726\",\"@Source\":\"PubMed\"},{\"$\":\"NBK258641\",\"@Source\":\"BookShelf\"}]}}","alternate_names":["ENCEPHALOPATHY, ACUTE NECROTIZING, SUSCEPTIBILITY TO","Susceptibility to Acute Necrotizing Encephalopathy 1"],"attribute_content":[]}
{"type":"Disease","keywords":[],"medgen_id":"C1832884","id":"5542","name":"Familial hemiplegic migraine type 1","alternate_symbols":["FHM","MHP1"],"symbol":"FHM1","gard_id":"2638","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0020756\"}","{\"db\":\"OMIM\",\"id\":\"141500\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"569\"}","{\"db\":\"OMIM\",\"id\":\"141500\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"FHM\"}","{\"db\":\"OMIM\",\"id\":\"141500\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"MHP1\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"2638\",\"ref_field\":\"gard_id\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Hemiplegic+migraine%2C+familial+type+1/3286\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1388\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"141500\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"public_definition":"Familial hemiplegic migraine (FHM) falls within the category of migraine with aura. In migraine with aura (including familial hemiplegic migraine) the neurologic symptoms of aura are unequivocally localizable to the cerebral cortex or brain stem and include visual disturbance (most common), sensory loss (e.g., numbness or paresthesias of the face or an extremity), and dysphasia (difficulty with speech); FHM must include motor involvement, i.e., hemiparesis (weakness of an extremity). Hemiparesis occurs with at least one other symptom during FHM aura. Neurologic deficits with FHM attacks can be prolonged for hours to days and may outlast the associated migrainous headache. FHM is often earlier in onset than typical migraine, frequently beginning in the first or second decade; the frequency of attacks tends to decrease with age. Approximately 40%-50% of families with FHM1 have cerebellar signs ranging from nystagmus to progressive, usually late-onset mild ataxia. Cerebral infarction and death have rarely been associated with hemiplegic migraine.","content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301562\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1388\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"EFNS, 2010\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"20298421\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"Orphanet, 2013\",\"@Type\":\"practice guideline\",\"CitationText\":{\"$\":\"Orphanet, Hemiplegic Migraine (HM), 2013\"},\"URL\":{\"$\":\"https://www.orpha.net/data/patho/Pro/en/Emergency_HemiplegicMigraine-enPro1031.pdf\"}}]}","alternate_names":["Migraine, familial hemiplegic 1, with progressive cerebellar ataxia"],"attribute_content":[]}
{"type":"Disease","keywords":[],"medgen_id":"C3809768","id":"18377","name":"Immunodeficiency 13","alternate_symbols":["ICL"],"symbol":"IMD13","gard_id":"12375","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0014226\"}","{\"db\":\"OMIM\",\"id\":\"615518\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"228000\"}","{\"db\":\"OMIM\",\"id\":\"615518\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"IDIOPATHIC CD4 LYMPHOPENIA\"}","{\"db\":\"OMIM\",\"id\":\"615518\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"ICL\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"12375\",\"ref_field\":\"gard_id\"}","{\"db\":\"OMIM\",\"id\":\"615518\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"alternate_names":["IDIOPATHIC CD4 LYMPHOPENIA"],"attribute_content":[]}
{"type":"Disease","keywords":[],"medgen_id":"C0270850","id":"1168","name":"Idiopathic generalized epilepsy","alternate_symbols":["IGE"],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0010918\"}","{\"db\":\"OMIM\",\"id\":\"600669\",\"type\":\"MIM\"}","{\"db\":\"OMIM\",\"id\":\"PS600669\",\"type\":\"Phenotypic series\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0010918\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"EIG\"}","{\"db\":\"OMIM\",\"id\":\"600669\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"EIG\"}","{\"db\":\"OMIM\",\"id\":\"600669\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"IGE\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Idiopathic+generalized+epilepsy/8637\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"36803009\",\"ref_field\":\"name\"}"],"alternate_names":["EIG"],"attribute_content":[]}
{"type":"Disease","keywords":[],"medgen_id":"C0431375","id":"2563","name":"Lissencephaly due to LIS1 mutation","alternate_symbols":["ILS"],"symbol":"LIS1","xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0006818\",\"type\":\"primary\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0011830\"}","{\"db\":\"OMIM\",\"id\":\"607432\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"95232\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK5189\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"LIS1-Associated Lissencephaly/Subcortical Band Heterotopia\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0006818\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Type 1 lissencephaly\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0006818\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Type I lissencephaly\"}","{\"db\":\"OMIM\",\"id\":\"607432\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"ILS\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0011830\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK5189\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"607432\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"public_definition":"PAFAH1B1-associated lissencephaly includes Miller-Dieker syndrome (MDS), isolated lissencephaly sequence (ILS), and (rarely) subcortical band heterotopia (SBH). Lissencephaly and SBH are cortical malformations caused by deficient neuronal migration during embryogenesis. Lissencephaly refers to a \"smooth brain\" with absent gyri (agyria) or abnormally wide gyri (pachygyria). SBH refers to a band of heterotopic gray matter located just beneath the cortex and separated from it by a thin zone of normal white matter. MDS is characterized by lissencephaly, typical facial features, and severe neurologic abnormalities. ILS is characterized by lissencephaly and its direct sequelae: developmental delay, intellectual disability, and seizures.","content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301752\",\"@Source\":\"PubMed\"},{\"$\":\"NBK5189\",\"@Source\":\"BookShelf\"}]}}","alternate_names":["Isolated Lissencephaly Sequence","LIS1-Associated Lissencephaly/Subcortical Band Heterotopia","Lissencephaly classic","Type 1 lissencephaly","Type I lissencephaly"],"attribute_content":[]}
{"type":"Disease","keywords":[],"medgen_id":"C2745948","id":"9509","name":"Hyaline fibromatosis syndrome","alternate_symbols":["JHF"],"symbol":"HFS","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0009229\"}","{\"db\":\"OMIM\",\"id\":\"228600\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"2028\"}","{\"db\":\"OMIM\",\"id\":\"228600\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HYALINOSIS, SYSTEMIC\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Fibromatosis+Juvenile+Hyaline/2851\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1525\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"228600\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"public_definition":"Inherited systemic hyalinosis is characterized by hyaline deposits in the papillary dermis and other tissues. It typically presents at birth or in infancy with severe pain with movement, progressive joint contractures, and often with severe motor disability, thickened skin, and hyperpigmented macules/patches over bony prominences of the joints. Gingival hypertrophy, skin nodules, pearly papules of the face and neck, and perianal masses are common. Complications of protein-losing enteropathy and failure to thrive can be life threatening. Cognitive development is normal. Many children with the severe form (previously called infantile systemic hyalinosis) die in early childhood; some with a milder phenotype (previously called juvenile hyaline fibromatosis) survive into adulthood.","content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301698\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1525\",\"@Source\":\"BookShelf\"}]}}","alternate_names":["HYALINOSIS, SYSTEMIC","Hyalinosis, systemic juvenile","Puretic syndrome"],"attribute_content":[]}
{"type":"Disease","keywords":[],"medgen_id":"C1266144","id":"5772","name":"Pleuropulmonary blastoma","alternate_symbols":["PPB"],"gard_id":"8757","xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0100528\",\"type\":\"primary\"}","{\"db\":\"Orphanet\",\"id\":\"64741\"}","{\"db\":\"Orphanet\",\"id\":\"64742\"}","{\"db\":\"OMIM\",\"id\":\"601200\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"PPB\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"8757\",\"ref_field\":\"gard_id\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Pleuropulmonary+blastoma/5804\",\"ref_field\":\"name\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0100528\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK196157\",\"ref_field\":\"public_definition\"}"],"public_definition":"DICER1 tumor predisposition (DICER1) is characterized by an increased risk for pleuropulmonary blastoma (PPB), pulmonary cysts, thyroid gland neoplasia (multinodular goiter, adenomas, and/or thyroid cancer), ovarian tumors (Sertoli-Leydig cell tumor, gynandroblastoma, and sarcoma), and cystic nephroma. Less commonly observed tumors include ciliary body medulloepithelioma, nasal chondromesenchymal hamartoma, embryonal rhabdomyosarcoma, pituitary blastoma, pineoblastoma, central nervous system (CNS) sarcoma, other CNS tumors, and presacral malignant teratoid tumor. The majority of tumors occur in individuals younger than age 40 years. PPB typically presents in infants and children younger than age six years. Ovarian sex cord-stromal tumors are most often diagnosed before age 40 years. Cystic nephroma generally presents in young children but has also been reported in adolescents. Additional clinical features that may be seen include macrocephaly, ocular abnormalities, structural anomalies of the kidney and collecting system, and dental anomalies (bulbous crowns).","content":"{\"Citation\":[{\"@Abbrev\":\"ASCO, 2014\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"24493721\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"24761742\",\"@Source\":\"PubMed\"},{\"$\":\"NBK196157\",\"@Source\":\"BookShelf\"}]}]}","alternate_names":[],"attribute_content":[]}
{"type":"Disease","keywords":[],"medgen_id":"C1859372","id":"643","name":"Calcification of joints and arteries","alternate_symbols":["ACDC"],"symbol":"CALJA","gard_id":"10762","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0008895\"}","{\"db\":\"OMIM\",\"id\":\"211800\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"289601\"}","{\"db\":\"OMIM\",\"id\":\"211800\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"ARTERIAL CALCIFICATION DUE TO DEFICIENCY OF CD73\"}","{\"db\":\"OMIM\",\"id\":\"211800\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"ACDC\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"10762\",\"ref_field\":\"gard_id\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Calcification+of+joints+and+arteries/7882\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"211800\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"alternate_names":["ARTERIAL CALCIFICATION DUE TO DEFICIENCY OF CD73"],"attribute_content":[]}
{"type":"Disease","keywords":[],"medgen_id":"C1843807","id":"585","name":"Biotin-responsive basal ganglia disease","alternate_symbols":["BBGD","BTBGD"],"symbol":"THMD2","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0011841\"}","{\"db\":\"OMIM\",\"id\":\"607483\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"199348\"}","{\"db\":\"Orphanet\",\"id\":\"65284\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Basal+Ganglia+Disease%2C+Biotin-Responsive/756\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Biotin-thiamine-responsive basal ganglia disease\"}","{\"db\":\"OMIM\",\"id\":\"607483\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"ENCEPHALOPATHY, THIAMINE-RESPONSIVE\"}","{\"db\":\"OMIM\",\"id\":\"606152.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"THIAMINE METABOLISM DYSFUNCTION SYNDROME 2 (BIOTIN- OR THIAMINE-RESPONSIVE TYPE)\"}","{\"db\":\"OMIM\",\"id\":\"606152.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"THIAMINE METABOLISM DYSFUNCTION SYNDROME 2 (BIOTIN- OR THIAMINE-RESPONSIVE TYPE)\"}","{\"db\":\"OMIM\",\"id\":\"606152.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"THIAMINE METABOLISM DYSFUNCTION SYNDROME 2 (BIOTIN- OR THIAMINE-RESPONSIVE TYPE)\"}","{\"db\":\"OMIM\",\"id\":\"606152.0004\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"THIAMINE METABOLISM DYSFUNCTION SYNDROME 2 (BIOTIN- OR THIAMINE-RESPONSIVE TYPE)\"}","{\"db\":\"OMIM\",\"id\":\"606152.0005\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"THIAMINE METABOLISM DYSFUNCTION SYNDROME 2 (BIOTIN- OR THIAMINE-RESPONSIVE TYPE)\"}","{\"db\":\"OMIM\",\"id\":\"606152.0006\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"THIAMINE METABOLISM DYSFUNCTION SYNDROME 2 (BIOTIN- OR THIAMINE-RESPONSIVE TYPE)\"}","{\"db\":\"OMIM\",\"id\":\"606152.0007\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"THIAMINE METABOLISM DYSFUNCTION SYNDROME 2 (BIOTIN- OR THIAMINE-RESPONSIVE TYPE)\"}","{\"db\":\"OMIM\",\"id\":\"607483\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"THIAMINE METABOLISM DYSFUNCTION SYNDROME 2 (BIOTIN- OR THIAMINE-RESPONSIVE TYPE)\"}","{\"db\":\"OMIM\",\"id\":\"607483\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"BBGD\"}","{\"db\":\"OMIM\",\"id\":\"607483\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"BTBGD\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0011841\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK169615\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"607483\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"public_definition":"Biotin-thiamine-responsive basal ganglia disease (BTBGD) may present in childhood, early infancy, or adulthood. The classic presentation of BTBGD occurs in childhood (age 3-10 years) and is characterized by recurrent subacute encephalopathy manifest as confusion, seizures, ataxia, dystonia, supranuclear facial palsy, external ophthalmoplegia, and/or dysphagia which, if left untreated, can eventually lead to coma and even death. Dystonia and cogwheel rigidity are nearly always present; hyperreflexia, ankle clonus, and Babinski responses are common. Hemiparesis or quadriparesis may be seen. Episodes are often triggered by febrile illness or mild trauma or stress. Simple partial or generalized seizures are easily controlled with antiepileptic drugs. An early-infantile Leigh-like syndrome / atypical infantile spasms presentation occurs in the first three months of life with poor feeding, vomiting, acute encephalopathy and severe lactic acidosis. An adult-onset Wernicke-like encephalopathy presentation is characterized by acute onset of status epilepticus, ataxia, nystagmus, diplopia, and ophthalmoplegia in the second decade of life. Prompt administration of biotin and thiamine early in the disease course results in partial or complete improvement within days in the childhood and adult presentations, but most with the infantile presentation have had poor outcome even after supplementation with biotin and thiamine.","content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"24260777\",\"@Source\":\"PubMed\"},{\"$\":\"NBK169615\",\"@Source\":\"BookShelf\"}]}}","alternate_names":["Biotin-thiamine-responsive basal ganglia disease","ENCEPHALOPATHY, THIAMINE-RESPONSIVE","THIAMINE METABOLISM DYSFUNCTION SYNDROME 2 (BIOTIN- OR THIAMINE-RESPONSIVE TYPE)","Thiamine Metabolism Dysfunction Syndrome 2","Thiamine metabolism dysfunction syndrome 2 (biotin- or thiamine-responsive encephalopathy type 2)"],"attribute_content":[]}
{"type":"Disease","keywords":[],"medgen_id":"C1868674","id":"5424","name":"Lymphoproliferative syndrome 1, X-linked","alternate_symbols":["EBVS","IMD5","LYP","XLP","XLPD"],"symbol":"XLP1","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0024551\"}","{\"db\":\"OMIM\",\"id\":\"308240\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"2442\"}","{\"db\":\"Orphanet\",\"id\":\"538931\"}","{\"db\":\"OMIM\",\"id\":\"308240\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"IMMUNODEFICIENCY 5\"}","{\"db\":\"OMIM\",\"id\":\"308240\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"IMMUNODEFICIENCY, X-LINKED PROGRESSIVE COMBINED VARIABLE\"}","{\"db\":\"OMIM\",\"id\":\"308240\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"INFECTIOUS MONONUCLEOSIS, SEVERE, SUSCEPTIBILITY TO\"}","{\"db\":\"OMIM\",\"id\":\"308240\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"EBVS\"}","{\"db\":\"OMIM\",\"id\":\"308240\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"IMD5\"}","{\"db\":\"OMIM\",\"id\":\"308240\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"LYP\"}","{\"db\":\"OMIM\",\"id\":\"308240\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"XLP\"}","{\"db\":\"OMIM\",\"id\":\"308240\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"XLPD\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Lymphoproliferative+syndrome+X-linked+1/4379\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1406\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"308240\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"public_definition":"X-linked lymphoproliferative disease (XLP) has two recognizable subtypes, XLP1 and XLP2. XLP1 is characterized predominantly by one of three commonly recognized phenotypes: Inappropriate immune response to Epstein-Barr virus (EBV) infection leading to hemophagocytic lymphohistiocytosis (HLH) or severe mononucleosis. Dysgammaglobulinemia. Lymphoproliferative disease (malignant lymphoma). XLP2 is most often characterized by HLH (often associated with EBV), dysgammaglobulinemia, and inflammatory bowel disease. HLH resulting from EBV infection is associated with an unregulated and exaggerated immune response with widespread proliferation of cytotoxic T cells, EBV-infected B cells, and macrophages. Dysgammaglobulinemia is typically hypogammaglobulinemia of one or more immunoglobulin subclasses. The malignant lymphomas are typically B-cell lymphomas, non-Hodgkin type, often extranodal, and in particular involving the intestine.","content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301580\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1406\",\"@Source\":\"BookShelf\"}]}}","alternate_names":["Duncan disease","Duncan's syndrome","EBV infection severe susceptibility to","Epstein Barr virus infection familial fatal","IMMUNODEFICIENCY 5","IMMUNODEFICIENCY, X-LINKED PROGRESSIVE COMBINED VARIABLE","INFECTIOUS MONONUCLEOSIS, SEVERE, SUSCEPTIBILITY TO","Purtilo syndrome"],"attribute_content":[]}
{"type":"Disease","keywords":[],"medgen_id":"C0751161","id":"1907","name":"UDPglucose-4-epimerase deficiency","alternate_symbols":["GALE"],"symbol":"GALAC3","gard_id":"5392","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0009257\"}","{\"db\":\"OMIM\",\"id\":\"230350\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"352\"}","{\"db\":\"Orphanet\",\"id\":\"79238\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK51671\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Epimerase Deficiency Galactosemia\"}","{\"db\":\"OMIM\",\"id\":\"230350\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"GALACTOSEMIA III\"}","{\"db\":\"OMIM\",\"id\":\"606953.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"GALACTOSEMIA III\"}","{\"db\":\"OMIM\",\"id\":\"606953.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"GALACTOSEMIA III\"}","{\"db\":\"OMIM\",\"id\":\"606953.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"GALACTOSEMIA III\"}","{\"db\":\"OMIM\",\"id\":\"606953.0004\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"GALACTOSEMIA III\"}","{\"db\":\"OMIM\",\"id\":\"606953.0005\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"GALACTOSEMIA III\"}","{\"db\":\"OMIM\",\"id\":\"606953.0006\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"GALACTOSEMIA III\"}","{\"db\":\"OMIM\",\"id\":\"606953.0007\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"GALACTOSEMIA III\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0009257\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Galactose epimerase deficiency\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000331211\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"GALE\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"5392\",\"ref_field\":\"gard_id\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Galactose+Epimerase+Deficiency/2972\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"8849004\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK51671\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"230350\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"public_definition":"Epimerase deficiency galactosemia (GALE deficiency galactosemia) is a continuum comprising three forms: Generalized. Enzyme activity is profoundly decreased in all tissues tested. Peripheral. Enzyme activity is deficient in red blood cells (RBC) and circulating white blood cells, but normal or near normal in all other tissues. Intermediate. Enzyme activity is deficient in red blood cells and circulating white blood cells and less than 50% of normal levels in other cells tested. Infants with generalized epimerase deficiency galactosemia develop clinical findings on a regular milk diet (which contains lactose, a disaccharide of galactose and glucose); manifestations include hypotonia, poor feeding, vomiting, weight loss, jaundice, hepatomegaly, liver dysfunction, aminoaciduria, and cataracts. Prompt removal of galactose/lactose from their diet resolves or prevents these acute symptoms. In contrast, neonates with the peripheral or intermediate form generally remain clinically well even on a regular milk diet and are usually only identified by biochemical testing, often in newborn screening programs.","content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"21290786\",\"@Source\":\"PubMed\"},{\"$\":\"NBK51671\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"ACMG ACT Sheet, 2010\",\"@Type\":\"practice guideline\",\"CitationText\":{\"$\":\"American College of Medical Genetics ACT SHEETs, Primary or Secondary Hypergalactosemia, 2010\"},\"URL\":{\"$\":\"https://www.ncbi.nlm.nih.gov/books/NBK55827/bin/Galactose_GALT.pdf\"}},{\"@Abbrev\":\"ACMG Algorithm, 2009\",\"@Type\":\"practice guideline\",\"CitationText\":{\"$\":\"American College of Medical Genetics Algorithm, Primary or Secondary Hypergalactosemia, 2009\"},\"URL\":{\"$\":\"https://www.ncbi.nlm.nih.gov/books/NBK55827/bin/Visio-GALT.pdf\"}}]}","alternate_names":["Epimerase Deficiency Galactosemia","GALACTOSEMIA III","Galactose epimerase deficiency","Galactosemia 3","UDP-Galactose-4-epimerase deficiency","UDPglucose 4-Epimerase Deficiency Disease"],"attribute_content":[]}
{"type":"Disease","keywords":[],"medgen_id":"C3538945","id":"2506","name":"Kaposi sarcoma, susceptibility to","alternate_symbols":["HHV8","KSHV"],"xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0100726\",\"type\":\"primary\"}","{\"db\":\"OMIM\",\"id\":\"148000\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"33276\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Classic+Kaposi+Sarcoma/1655\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Classic Kaposi sarcoma\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0100726\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Kaposi's sarcoma\"}","{\"db\":\"OMIM\",\"id\":\"148000\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MULTIPLE IDIOPATHIC PIGMENTED HEMANGIOSARCOMA, SUSCEPTIBILITY TO\"}","{\"db\":\"OMIM\",\"id\":\"148000\",\"type\":\"MIM\",\"ref_field\":\"public_definition\"}"],"public_definition":"Kaposi sarcoma (KS) is an invasive angioproliferative inflammatory condition that occurs commonly in men infected with human immunodeficiency virus (HIV; see 609423). In the early stages of KS, lesions appear reactive and are stimulated to grow by the actions of inflammatory cytokines and growth factors. In the late stages of KS, a malignant phenotype that appears to be monoclonal can develop. Infection with human herpesvirus-8 (HHV-8), also known as KS-associated herpesvirus (KSHV), is necessary but not sufficient for KS development. Coinfection with HIV markedly increases the likelihood of KS development, and additional environmental, hormonal, and genetic cofactors likely contribute to its pathogenesis (summary by Foster et al., 2000).\r\nSuthaus et al. (2012) noted that HHV-8 is the etiologic agent not only of KS, but also of primary effusion lymphoma and plasma cell-type multicentric Castleman disease (MCD).","alternate_names":["Classic Kaposi sarcoma","Human herpesvirus 8","Kaposi's sarcoma","MULTIPLE IDIOPATHIC PIGMENTED HEMANGIOSARCOMA, SUSCEPTIBILITY TO","Mediterranean Kaposi sarcoma","Non AIDS related Kaposi sarcoma"],"attribute_content":[]}
{"type":"Disease","keywords":[],"medgen_id":"C4551968","id":"2610","name":"Lissencephaly, X-linked","alternate_symbols":["LISX","XLIS"],"symbol":"LISX1","gard_id":"6914","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0010239\"}","{\"db\":\"OMIM\",\"id\":\"300067\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"2148\"}","{\"db\":\"OMIM\",\"id\":\"300067\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"LISSENCEPHALY, X-LINKED, 1\"}","{\"db\":\"OMIM\",\"id\":\"300121.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"LISSENCEPHALY, X-LINKED, 1\"}","{\"db\":\"OMIM\",\"id\":\"300121.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"LISSENCEPHALY, X-LINKED, 1\"}","{\"db\":\"OMIM\",\"id\":\"300121.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"LISSENCEPHALY, X-LINKED, 1\"}","{\"db\":\"OMIM\",\"id\":\"300121.0005\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"LISSENCEPHALY, X-LINKED, 1\"}","{\"db\":\"OMIM\",\"id\":\"300121.0006\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"LISSENCEPHALY, X-LINKED, 1\"}","{\"db\":\"OMIM\",\"id\":\"300121.0007\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"LISSENCEPHALY, X-LINKED, 1\"}","{\"db\":\"OMIM\",\"id\":\"300121.0013\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"LISSENCEPHALY, X-LINKED, 1\"}","{\"db\":\"OMIM\",\"id\":\"300121.0014\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"LISSENCEPHALY, X-LINKED, 1\"}","{\"db\":\"OMIM\",\"id\":\"300067\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"XLIS\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"6914\",\"ref_field\":\"gard_id\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Lissencephaly+X-linked/4273\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1185\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"300067\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"public_definition":"DCX-related disorders include the neuronal migration disorders: Classic thick lissencephaly (more severe anteriorly), usually in males. Subcortical band heterotopia (SBH), primarily in females. Males with classic DCX-related lissencephaly typically have early and profound cognitive and language impairment, cerebral palsy, and epileptic seizures. The clinical phenotype in females with SBH varies widely with cognitive abilities that range from average or mild cognitive impairment to severe intellectual disability and language impairment. Seizures, which frequently are refractory to antiepileptic medication, may be either focal or generalized and behavioral problems may also be observed. In DCX-related lissencephaly and SBH the severity of the clinical manifestation correlates roughly with the degree of the underlying brain malformation as observed in cerebral imaging.","content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301364\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1185\",\"@Source\":\"BookShelf\"}]}}","alternate_names":["LISSENCEPHALY, X-LINKED, 1","Lissencephaly and agenesis of corpus callosum"],"attribute_content":[]}
{"type":"Disease","keywords":[],"medgen_id":"C4551825","id":"2837","name":"Megaloblastic anemia due to inborn errors of metabolism","alternate_symbols":["MGA1"],"gard_id":"7006","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0009853\"}","{\"db\":\"Orphanet\",\"id\":\"35858\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0009853\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Imerslund-Grasbeck syndrome\"}","{\"db\":\"OMIM\",\"id\":\"261100\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MEGALOBLASTIC ANEMIA, FINNISH TYPE\"}","{\"db\":\"OMIM\",\"id\":\"250950\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"MGA1\"}","{\"db\":\"OMIM\",\"id\":\"261100\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"MGA1\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"7006\",\"ref_field\":\"gard_id\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Megaloblastic+anemia+due+to+inborn+errors+of+metabolism/8803\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"34925000\",\"ref_field\":\"name\"}"],"alternate_names":["Enterocyte cobalamin malabsorption","Enterocyte intrinsic factor receptor, defect of","Imerslund-Grasbeck syndrome","MEGALOBLASTIC ANEMIA, FINNISH TYPE","Pernicious anemia, juvenile, due to selective intestinal malabsorption of vitamin b12, with proteinuria"],"attribute_content":[]}
{"type":"Disease","keywords":[],"medgen_id":"C3714927","id":"3052","name":"Multiple system atrophy","alternate_symbols":["MSA1"],"symbol":"MSA","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0007803\"}","{\"db\":\"OMIM\",\"id\":\"146500\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"102\"}","{\"db\":\"OMIM\",\"id\":\"146500\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MSA1, SUSCEPTIBILITY TO\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Shy-Drager+syndrome/6584\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Shy-Drager syndrome\"}","{\"db\":\"SNOMED CT\",\"id\":\"16576004\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Shy-Drager syndrome\"}","{\"db\":\"OMIM\",\"id\":\"146500\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"MSA1\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0007803\",\"ref_field\":\"name\"}"],"alternate_names":["MSA1, SUSCEPTIBILITY TO","Multiple system atrophy (MSA) with orthostatic hypotension","Multiple system atrophy with autonomic failure","Orthostatic hypotension, bladder and bowel incontinence, anhidrosis, iris atrophy, amyotrophy, ataxia, rigidity and tremor","Shy-Drager syndrome"],"attribute_content":[]}
{"type":"Disease","keywords":[],"medgen_id":"C1864445","id":"5258","name":"Histiocytosis-lymphadenopathy plus syndrome","alternate_symbols":["PHID","SHML"],"symbol":"HJCD","gard_id":"10239","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0011273\"}","{\"db\":\"OMIM\",\"id\":\"602782\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"168569\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0011273\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"H syndrome\"}","{\"db\":\"OMIM\",\"id\":\"602782\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HISTIOCYTOSIS AND LYMPHADENOPATHY WITH OR WITHOUT CUTANEOUS, CARDIAC, AND/OR ENDOCRINE FEATURES, JOINT CONTRACTURES, AND/OR DEAFNESS\"}","{\"db\":\"OMIM\",\"id\":\"602782\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HYPERPIGMENTATION, CUTANEOUS, WITH HYPERTRICHOSIS, HEPATOSPLENOMEGALY, HEART ANOMALIES, AND HYPOGONADISM WITH OR WITHOUT HEARING LOSS\"}","{\"db\":\"OMIM\",\"id\":\"612391\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HYPERPIGMENTATION, CUTANEOUS, WITH HYPERTRICHOSIS, HEPATOSPLENOMEGALY, HEART ANOMALIES, AND HYPOGONADISM WITH OR WITHOUT HEARING LOSS\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Histiocytosis+with+joint+contractures+and+sensorineural+deafness/3435\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Histiocytosis with joint contractures and sensorineural deafness\"}","{\"db\":\"OMIM\",\"id\":\"602782\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"PIGMENTED HYPERTRICHOSIS WITH INSULIN-DEPENDENT DIABETES MELLITUS\"}","{\"db\":\"OMIM\",\"id\":\"602782\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"ROSAI-DORFMAN DISEASE, FAMILIAL\"}","{\"db\":\"OMIM\",\"id\":\"602782\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"SINUS HISTIOCYTOSIS AND MASSIVE LYMPHADENOPATHY\"}","{\"db\":\"OMIM\",\"id\":\"602782\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"PHID\"}","{\"db\":\"OMIM\",\"id\":\"612391\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"PHID\"}","{\"db\":\"OMIM\",\"id\":\"602782\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"SHML\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"10239\",\"ref_field\":\"gard_id\"}","{\"db\":\"OMIM\",\"id\":\"602782\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"alternate_names":["Asrar Facharzt Haque syndrome","Faisalabad histiocytosis","H syndrome","HISTIOCYTOSIS AND LYMPHADENOPATHY WITH OR WITHOUT CUTANEOUS, CARDIAC, AND/OR ENDOCRINE FEATURES, JOINT CONTRACTURES, AND/OR DEAFNESS","HYPERPIGMENTATION, CUTANEOUS, WITH HYPERTRICHOSIS, HEPATOSPLENOMEGALY, HEART ANOMALIES, AND HYPOGONADISM WITH OR WITHOUT HEARING LOSS","Histiocytosis with joint contractures and sensorineural deafness","Hyperpigmentation, Cutaneous, with Hypertrichosis, Hepatosplenomegaly, Heart Anomalies, Hearing Loss, and Hypogonadism","PIGMENTED HYPERTRICHOSIS WITH INSULIN-DEPENDENT DIABETES MELLITUS","Pigmented hypertrichosis and insulin-dependent diabetes mellitus","ROSAI-DORFMAN DISEASE, FAMILIAL","SINUS HISTIOCYTOSIS AND MASSIVE LYMPHADENOPATHY"],"attribute_content":["{\"Attribute\":{\"@Type\":\"GARD id\",\"@integerValue\":\"581\"},\"XRef\":{\"@DB\":\"Office of Rare Diseases\",\"@ID\":\"581\"}}"]}
{"type":"Disease","keywords":[],"medgen_id":"C0024408","id":"5426","name":"Azorean disease","alternate_symbols":["SCA3"],"symbol":"MJD","gard_id":"6801","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0007182\"}","{\"db\":\"OMIM\",\"id\":\"109150\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"98757\"}","{\"db\":\"OMIM\",\"id\":\"109150\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"SPINOCEREBELLAR ATROPHY III\"}","{\"db\":\"OMIM\",\"id\":\"109150\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"SCA3\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"6801\",\"ref_field\":\"gard_id\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Spinocerebellar+ataxia+3/6762\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"91952008\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1196\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"109150\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"public_definition":"Spinocerebellar ataxia type 3 (SCA3), also known as Machado-Joseph disease (MJD), is characterized by progressive cerebellar ataxia and variable findings including pyramidal signs, a dystonic-rigid extrapyramidal syndrome, significant peripheral amyotrophy and generalized areflexia, progressive external ophthalmoplegia, action-induced facial and lingual fasciculations, and bulging eyes. Neurologic findings tend to evolve as the disorder progresses.","content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301375\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1196\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301317\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1138\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"EFNS, 2010\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"20050888\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"EFNS/ENS, 2014\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"24418350\",\"@Source\":\"PubMed\"}}]}","alternate_names":["Azorean neurologic disease","Machado-Joseph Disease","Nigrospinodentatal degeneration","SPINOCEREBELLAR ATROPHY III","Spinocerebellar atrophy type 3","Spinopontine atrophy"],"attribute_content":[]}
{"type":"Disease","keywords":[],"medgen_id":"C1836705","id":"4055","name":"Pseudohyperkalemia, familial, 2, due to red cell leak","alternate_symbols":["ABCB6"],"symbol":"PSHK2","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0012204\"}","{\"db\":\"OMIM\",\"id\":\"609153\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"90044\"}","{\"db\":\"OMIM\",\"id\":\"609153\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CRYOHYDROCYTOSIS, MILD\"}","{\"db\":\"OMIM\",\"id\":\"609153\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"PSEUDOHYPERKALEMIA EAST LONDON\"}","{\"db\":\"OMIM\",\"id\":\"609153\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"PSEUDOHYPERKALEMIA LILLE\"}","{\"db\":\"OMIM\",\"id\":\"609153\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"alternate_names":["CRYOHYDROCYTOSIS, MILD","PSEUDOHYPERKALEMIA EAST LONDON","PSEUDOHYPERKALEMIA LILLE","Pseudohyperkalemia Chiswick","Pseudohyperkalemia Falkirk"],"attribute_content":[]}
{"type":"Disease","keywords":[],"medgen_id":"C4014869","id":"31859","name":"Familial partial lipodystrophy 6","alternate_symbols":["AOMS4"],"symbol":"FPLD6","gard_id":"13126","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0014431\"}","{\"db\":\"OMIM\",\"id\":\"615980\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"435660\"}","{\"db\":\"OMIM\",\"id\":\"615980\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"LIPODYSTROPHY, FAMILIAL PARTIAL, ASSOCIATED WITH LIPE MUTATIONS\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"13126\",\"ref_field\":\"gard_id\"}","{\"db\":\"OMIM\",\"id\":\"615980\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"alternate_names":["Abdominal obesity-metabolic syndrome 4","LIPODYSTROPHY, FAMILIAL PARTIAL, ASSOCIATED WITH LIPE MUTATIONS"],"attribute_content":[]}
{"type":"Disease","keywords":[],"medgen_id":"C0265325","id":"3207","name":"Turcot syndrome","disease_mechanism":"loss of function","alternate_symbols":["BTPS1","CMMRDS","MSH2","MSH6"],"symbol":"MMRCS","gard_id":"420","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0010159\"}","{\"db\":\"OMIM\",\"id\":\"276300\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"252202\"}","{\"db\":\"OMIM\",\"id\":\"276300\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"BRAIN TUMOR-POLYPOSIS SYNDROME 1\"}","{\"db\":\"OMIM\",\"id\":\"276300\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"BTP1 SYNDROME\"}","{\"db\":\"OMIM\",\"id\":\"276300\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CHILDHOOD CANCER SYNDROME\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0010159\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Constitutional mismatch repair deficiency syndrome\"}","{\"db\":\"Orphanet\",\"id\":\"252202\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Constitutional mismatch repair deficiency syndrome\"}","{\"db\":\"OMIM\",\"id\":\"120436.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MISMATCH REPAIR CANCER SYNDROME\"}","{\"db\":\"OMIM\",\"id\":\"120436.0010\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MISMATCH REPAIR CANCER SYNDROME\"}","{\"db\":\"OMIM\",\"id\":\"120436.0011\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MISMATCH REPAIR CANCER SYNDROME\"}","{\"db\":\"OMIM\",\"id\":\"120436.0014\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MISMATCH REPAIR CANCER SYNDROME\"}","{\"db\":\"OMIM\",\"id\":\"120436.0020\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MISMATCH REPAIR CANCER SYNDROME\"}","{\"db\":\"OMIM\",\"id\":\"120436.0027\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MISMATCH REPAIR CANCER SYNDROME\"}","{\"db\":\"OMIM\",\"id\":\"120436.0028\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MISMATCH REPAIR CANCER SYNDROME\"}","{\"db\":\"OMIM\",\"id\":\"120436.0034\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MISMATCH REPAIR CANCER SYNDROME\"}","{\"db\":\"OMIM\",\"id\":\"276300\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MISMATCH REPAIR CANCER SYNDROME\"}","{\"db\":\"OMIM\",\"id\":\"600259.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MISMATCH REPAIR CANCER SYNDROME\"}","{\"db\":\"OMIM\",\"id\":\"600259.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MISMATCH REPAIR CANCER SYNDROME\"}","{\"db\":\"OMIM\",\"id\":\"600259.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MISMATCH REPAIR CANCER SYNDROME\"}","{\"db\":\"OMIM\",\"id\":\"600259.0004\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MISMATCH REPAIR CANCER SYNDROME\"}","{\"db\":\"OMIM\",\"id\":\"600259.0005\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MISMATCH REPAIR CANCER SYNDROME\"}","{\"db\":\"OMIM\",\"id\":\"600259.0011\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MISMATCH REPAIR CANCER SYNDROME\"}","{\"db\":\"OMIM\",\"id\":\"600259.0012\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MISMATCH REPAIR CANCER SYNDROME\"}","{\"db\":\"OMIM\",\"id\":\"600259.0013\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MISMATCH REPAIR CANCER SYNDROME\"}","{\"db\":\"OMIM\",\"id\":\"600259.0014\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MISMATCH REPAIR CANCER SYNDROME\"}","{\"db\":\"OMIM\",\"id\":\"600259.0016\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MISMATCH REPAIR CANCER SYNDROME\"}","{\"db\":\"OMIM\",\"id\":\"600259.0017\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MISMATCH REPAIR CANCER SYNDROME\"}","{\"db\":\"OMIM\",\"id\":\"600259.0018\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MISMATCH REPAIR CANCER SYNDROME\"}","{\"db\":\"OMIM\",\"id\":\"600259.0019\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MISMATCH REPAIR CANCER SYNDROME\"}","{\"db\":\"OMIM\",\"id\":\"600678.0012\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MISMATCH REPAIR CANCER SYNDROME\"}","{\"db\":\"OMIM\",\"id\":\"600678.0013\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MISMATCH REPAIR CANCER SYNDROME\"}","{\"db\":\"OMIM\",\"id\":\"600678.0014\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MISMATCH REPAIR CANCER SYNDROME\"}","{\"db\":\"OMIM\",\"id\":\"600678.0015\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MISMATCH REPAIR CANCER SYNDROME\"}","{\"db\":\"OMIM\",\"id\":\"600678.0016\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MISMATCH REPAIR CANCER SYNDROME\"}","{\"db\":\"OMIM\",\"id\":\"600678.0017\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MISMATCH REPAIR CANCER SYNDROME\"}","{\"db\":\"OMIM\",\"id\":\"609309.0014\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MISMATCH REPAIR CANCER SYNDROME\"}","{\"db\":\"OMIM\",\"id\":\"609309.0015\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MISMATCH REPAIR CANCER SYNDROME\"}","{\"db\":\"OMIM\",\"id\":\"609309.0016\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MISMATCH REPAIR CANCER SYNDROME\"}","{\"db\":\"OMIM\",\"id\":\"609309.0020\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MISMATCH REPAIR CANCER SYNDROME\"}","{\"db\":\"OMIM\",\"id\":\"276300\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MISMATCH REPAIR DEFICIENCY\"}","{\"db\":\"OMIM\",\"id\":\"276300\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MMR DEFICIENCY\"}","{\"db\":\"OMIM\",\"id\":\"276300\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"BTPS1\"}","{\"db\":\"OMIM\",\"id\":\"276300\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"CMMRDS\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000317455\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"MSH2\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000317455\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000317457\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000328927\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000501396\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000501398\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000501399\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000501400\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000501401\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000501402\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000501424\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000501797\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000515534\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000515899\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000518997\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000520069\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000527981\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000527982\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000527984\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000528519\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000528912\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000528914\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000528915\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000528930\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000529017\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000530120\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000530202\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000569423\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"420\",\"ref_field\":\"gard_id\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Turcot+syndrome/7267\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"61665008\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1211\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"276300\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"disease_mechanism_id":"273","public_definition":"Lynch syndrome is characterized by an increased risk for colorectal cancer (CRC) and cancers of the endometrium, stomach, ovary, small bowel, hepatobiliary tract, urinary tract, brain, and skin. In individuals with Lynch syndrome the following lifetime risks for cancer are seen: CRC: 52%-82% (mean age at diagnosis 44-61 years). Endometrial cancer in females: 25%-60% (mean age at diagnosis 48-62 years). Gastric cancer: 6%-13% (mean age at diagnosis 56 years). Ovarian cancer: 4%-12% (mean age at diagnosis 42.5 years; ~30% are diagnosed \u003c age 40 years). The risk for other Lynch syndrome-related cancers is lower, though substantially increased over general population rates.","content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301390\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1211\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"NSGC, 2004\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"15604628\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ACMG/NSGC, 2015\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"25394175\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ASCO/ESMO, 2015\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"25452455\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"NSGC/CCA-ICC, 2012\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"22167527\",\"@Source\":\"PubMed\"}}]}","alternate_names":["BRAIN TUMOR-POLYPOSIS SYNDROME 1","BTP1 SYNDROME","CHILDHOOD CANCER SYNDROME","CNS tumors with Familial polyposis of the colon","Constitutional mismatch repair deficiency syndrome","MISMATCH REPAIR CANCER SYNDROME","MISMATCH REPAIR DEFICIENCY","MLH1-Related Hereditary Non-Polyposis Colon Cancer","MLH1-Related Turcot Syndrome","MMR DEFICIENCY","MSH2-Related Turcot Syndrome","MSH6-Related Hereditary Non-Polyposis Colon Cancer","MSH6-Related Turcot Syndrome","Malignant tumors of the central nervous system associated with familial polyposis of the colon","PMS2-Related Hereditary Non-Polyposis Colon Cancer","PMS2-Related Lynch Syndrome","PMS2-Related Turcot Syndrome"],"attribute_content":[]}
{"type":"Disease","keywords":[],"medgen_id":"C3554385","id":"17567","name":"Congenital disorder of glycosylation type 1u","alternate_symbols":["CDGIu"],"symbol":"CDG1U","gard_id":"12416","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0014023\"}","{\"db\":\"OMIM\",\"id\":\"615042\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"329178\"}","{\"db\":\"OMIM\",\"id\":\"615042\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CDG Iu\"}","{\"db\":\"OMIM\",\"id\":\"615042\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"CDGIu\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"12416\",\"ref_field\":\"gard_id\"}","{\"db\":\"OMIM\",\"id\":\"615042\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301507\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1332\",\"@Source\":\"BookShelf\"}]}}","alternate_names":["CDG Iu"],"attribute_content":[]}
{"type":"Disease","keywords":[],"medgen_id":"C0282102","id":"800","name":"Chondrodysplasia punctata 2 X-linked dominant","alternate_symbols":["CDPXD","CPXD"],"symbol":"CDPX2","gard_id":"6189","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0020603\"}","{\"db\":\"OMIM\",\"id\":\"302960\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"35173\"}","{\"db\":\"OMIM\",\"id\":\"302960\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CONRADI-HUNERMANN-HAPPLE SYNDROME\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0020603\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"X-linked chondrodysplasia punctata 2\"}","{\"db\":\"OMIM\",\"id\":\"302960\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"CDPXD\"}","{\"db\":\"OMIM\",\"id\":\"302960\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"CPXD\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"6189\",\"ref_field\":\"gard_id\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Chondrodysplasia+Punctata+2+X-Linked+Dominant/1368\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK55062\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"302960\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"public_definition":"The findings in X-linked chondrodysplasia punctata 2 (CDPX2) range from fetal demise with multiple malformations and severe growth retardation to much milder manifestations, including females with no recognizable physical abnormalities. At least 95% of liveborn individuals with CDPX2 are female. Characteristic features include growth deficiency; distinctive craniofacial appearance; chondrodysplasia punctata (stippling of the epiphyses of the long bones, vertebrae, trachea, and distal ends of the ribs); often asymmetric rhizomelic shortening of limbs; scoliosis; linear or blotchy scaling ichthyosis in the newborn; later appearance of linear or whorled atrophic patches involving hair follicles (follicular atrophoderma); coarse hair with scarring alopecia; and cataracts.","content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"21634086\",\"@Source\":\"PubMed\"},{\"$\":\"NBK55062\",\"@Source\":\"BookShelf\"}]}}","alternate_names":["CONRADI-HUNERMANN-HAPPLE SYNDROME","Chondrodysplasia punctata, X-linked dominant","Conrad Hunermann Happle syndrome","Happle syndrome","Hunermann-Conradi Syndrome","X-linked chondrodysplasia punctata 2"],"attribute_content":[]}
{"type":"Disease","keywords":[],"medgen_id":"C3554686","id":"17786","name":"Immunodeficiency 11","alternate_symbols":["IMD11"],"symbol":"IMD11A","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0014081\"}","{\"db\":\"OMIM\",\"id\":\"615206\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"357237\"}","{\"db\":\"OMIM\",\"id\":\"607210.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"IMMUNODEFICIENCY 11A\"}","{\"db\":\"OMIM\",\"id\":\"607210.0004\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"IMMUNODEFICIENCY 11A\"}","{\"db\":\"OMIM\",\"id\":\"615206\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"IMD11\"}","{\"db\":\"OMIM\",\"id\":\"615206\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"alternate_names":["IMMUNODEFICIENCY 11A"],"attribute_content":[]}
{"type":"Disease","keywords":[],"medgen_id":"C1846790","id":"2499","name":"Joubert syndrome 4","alternate_symbols":["NPHP1"],"symbol":"JBTS4","gard_id":"10169","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0012308\"}","{\"db\":\"OMIM\",\"id\":\"609583\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"220497\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"10169\",\"ref_field\":\"gard_id\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Joubert+syndrome+4/3921\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1325\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"609583\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"public_definition":"Classic Joubert syndrome (JS) is characterized by three primary findings: A distinctive cerebellar and brain stem malformation called the molar tooth sign (MTS). Hypotonia. Developmental delays. Often these findings are accompanied by episodic tachypnea or apnea and/or atypical eye movements. In general, the breathing abnormalities improve with age, truncal ataxia develops over time, and acquisition of gross motor milestones is delayed. Cognitive abilities are variable, ranging from severe intellectual disability to normal. Additional findings can include retinal dystrophy, renal disease, ocular colobomas, occipital encephalocele, hepatic fibrosis, polydactyly, oral hamartomas, and endocrine abnormalities. Both intra- and interfamilial variation are seen.","content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301500\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1325\",\"@Source\":\"BookShelf\"}]}}","alternate_names":["Joubert syndrome with renal anomalies"],"attribute_content":[]}
{"type":"Disease","keywords":[],"medgen_id":"C3280887","id":"16815","name":"Pyruvate dehydrogenase lipoic acid synthetase deficiency","alternate_symbols":["PDHLD"],"symbol":"HGCLAS","gard_id":"12678","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0013762\"}","{\"db\":\"OMIM\",\"id\":\"614462\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"401859\"}","{\"db\":\"OMIM\",\"id\":\"607031.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HYPERGLYCINEMIA, LACTIC ACIDOSIS, AND SEIZURES\"}","{\"db\":\"OMIM\",\"id\":\"607031.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HYPERGLYCINEMIA, LACTIC ACIDOSIS, AND SEIZURES\"}","{\"db\":\"OMIM\",\"id\":\"607031.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HYPERGLYCINEMIA, LACTIC ACIDOSIS, AND SEIZURES\"}","{\"db\":\"OMIM\",\"id\":\"614462\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HYPERGLYCINEMIA, LACTIC ACIDOSIS, AND SEIZURES\"}","{\"db\":\"OMIM\",\"id\":\"614462\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"PDHLD\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"12678\",\"ref_field\":\"gard_id\"}","{\"db\":\"Genetic Alliance\",\"id\":\"PYRUVATE+DEHYDROGENASE+LIPOIC+ACID+SYNTHETASE+DEFICIENCY/9203\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"614462\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"alternate_names":["HYPERGLYCINEMIA, LACTIC ACIDOSIS, AND SEIZURES"],"attribute_content":[]}
{"type":"Disease","keywords":[],"medgen_id":"C1833030","id":"3754","name":"Nonepidermolytic palmoplantar keratoderma","alternate_symbols":["PPKNE","TYLOSIS"],"symbol":"NEPPK","xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0007404\",\"type\":\"primary\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0006588\"}","{\"db\":\"OMIM\",\"id\":\"600962\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"2337\"}","{\"db\":\"OMIM\",\"id\":\"600962\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"PPKNE\"}","{\"db\":\"OMIM\",\"id\":\"600962\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"TYLOSIS\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0007404\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"600962\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"alternate_names":[],"attribute_content":[]}
{"type":"Disease","keywords":[],"medgen_id":"C2673635","id":"4831","name":"Combined saposin deficiency","alternate_symbols":["PSAPD"],"gard_id":"12505","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0012719\"}","{\"db\":\"OMIM\",\"id\":\"611721\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"139406\"}","{\"db\":\"OMIM\",\"id\":\"611721\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"COMBINED SAP DEFICIENCY\"}","{\"db\":\"OMIM\",\"id\":\"611721\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"PROSAPOSIN DEFICIENCY\"}","{\"db\":\"OMIM\",\"id\":\"611721\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"PSAPD\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"12505\",\"ref_field\":\"gard_id\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Combined+saposin+deficiency/8022\",\"ref_field\":\"name\"}"],"alternate_names":["COMBINED SAP DEFICIENCY","PROSAPOSIN DEFICIENCY"],"attribute_content":[]}
{"type":"Disease","keywords":[],"medgen_id":"C2677589","id":"5960","name":"Coenzyme Q10 deficiency, primary, 4","alternate_symbols":["SCAR9"],"symbol":"COQ10D4","gard_id":"10294","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0012784\"}","{\"db\":\"OMIM\",\"id\":\"612016\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"139485\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Spinocerebellar+ataxia%2C+autosomal+recessive+9/9342\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Spinocerebellar ataxia, autosomal recessive 9\"}","{\"db\":\"OMIM\",\"id\":\"612016\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"SCAR9\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"10294\",\"ref_field\":\"gard_id\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK410087\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"612016\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"public_definition":"Primary coenzyme Q10 (CoQ10) deficiency is usually associated with multisystem involvement, including neurologic manifestations such as fatal neonatal encephalopathy with hypotonia; a late-onset slowly progressive multiple-system atrophy-like phenotype (neurodegeneration with autonomic failure and various combinations of parkinsonism and cerebellar ataxia, and pyramidal dysfunction); and dystonia, spasticity, seizures, and intellectual disability. Steroid-resistant nephrotic syndrome (SRNS), the hallmark renal manifestation, is often the initial manifestation either as isolated renal involvement that progresses to end-stage renal disease (ESRD), or associated with encephalopathy (seizures, stroke-like episodes, severe neurologic impairment) resulting in early death. Hypertrophic cardiomyopathy (HCM), retinopathy or optic atrophy, and sensorineural hearing loss can also be seen.","content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"28125198\",\"@Source\":\"PubMed\"},{\"$\":\"NBK410087\",\"@Source\":\"BookShelf\"}]}}","alternate_names":["Spinocerebellar ataxia, autosomal recessive 9"],"attribute_content":[]}
{"type":"Disease","keywords":[],"medgen_id":"C3806402","id":"5374","name":"Epilepsy, focal, with speech disorder and with or without mental retardation","alternate_symbols":["ADRESD","EPND","LKS","RESDAD"],"symbol":"FESD","gard_id":"6855","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0009509\"}","{\"db\":\"OMIM\",\"id\":\"245570\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"1945\"}","{\"db\":\"Orphanet\",\"id\":\"725\"}","{\"db\":\"Orphanet\",\"id\":\"98818\"}","{\"db\":\"OMIM\",\"id\":\"245570\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"APHASIA, ACQUIRED, WITH EPILEPSY\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Epilepsy+with+neurodevelopmental+defects/8322\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Epilepsy with neurodevelopmental defects\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Landau-Kleffner+syndrome/4080\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Landau-Kleffner syndrome\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0009509\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Landau-Kleffner syndrome\"}","{\"db\":\"OMIM\",\"id\":\"245570\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"ADRESD\"}","{\"db\":\"OMIM\",\"id\":\"613971\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"EPND\"}","{\"db\":\"OMIM\",\"id\":\"245570\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"LKS\"}","{\"db\":\"OMIM\",\"id\":\"245570\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"RESDAD\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"6855\",\"ref_field\":\"gard_id\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK385627\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"245570\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"public_definition":"GRIN2A-related speech disorders and epilepsy are characterized by speech disorders in all affected individuals and a range of epilepsy syndromes present in about 90%. Severe speech disorders observed can include dysarthria and speech dyspraxia, and both receptive and expressive language delay/regression; more mildly affected individuals may display subtly impaired intelligibility of conversational speech. Epilepsy features include seizure onset usually between ages three and six years, focal epilepsy with language and/or global developmental regression, and electroencephalogram (EEG) showing continuous spike-and-wave discharges in sleep or very active centrotemporal discharges. Seizure types include seizures associated with aura of perioral paresthesia, focal or focal motor seizures (often evolving to generalized tonic-clonic), and atypical absence seizures. Epilepsy syndromes can include: Landau-Kleffner syndrome (LKS), epileptic encephalopathy with continuous spike-and-wave during sleep (ECSWS), childhood epilepsy with centrotemporal spikes (CECTS), atypical childhood epilepsy with centrotemporal spikes (ACECTS), autosomal dominant rolandic epilepsy with speech dyspraxia (ADRESD), and infantile-onset epileptic encephalopathy.","content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"27683935\",\"@Source\":\"PubMed\"},{\"$\":\"NBK385627\",\"@Source\":\"BookShelf\"}]}}","alternate_names":["APHASIA, ACQUIRED, WITH EPILEPSY","Acquired aphasia with convulsive disorder","Acquired epileptiform aphasia","Epilepsy with neurodevelopmental defects","GRIN2A-Related Disorders","Landau-Kleffner syndrome","Rolandic epilepsy, mental retardation, and speech dyspraxia, autosomal dominant"],"attribute_content":[]}
{"type":"Disease","keywords":[],"medgen_id":"C1857587","id":"838","name":"Congenital heart defects, hamartomas of tongue, and polysyndactyly","alternate_symbols":["CHDTHP"],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0009008\"}","{\"db\":\"OMIM\",\"id\":\"217085\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"1338\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0009008\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Heart defect - tongue hamartoma - polysyndactyly syndrome\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Orstavik+Lindemann+Solberg+syndrome/5435\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Orstavik Lindemann Solberg syndrome\"}","{\"db\":\"OMIM\",\"id\":\"217085\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"CHDTHP\"}"],"alternate_names":["Heart defect - tongue hamartoma - polysyndactyly syndrome","Orstavik Lindemann Solberg syndrome"],"attribute_content":[]}
{"type":"Disease","keywords":[],"medgen_id":"C3151085","id":"10145","name":"MASP2 deficiency","alternate_symbols":["LCAPD2"],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0013423\"}","{\"db\":\"OMIM\",\"id\":\"613791\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"331187\"}","{\"db\":\"OMIM\",\"id\":\"613791\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"LECTIN COMPLEMENT ACTIVATION PATHWAY, DEFECT IN, 2\"}","{\"db\":\"OMIM\",\"id\":\"613791\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"LCAPD2\"}"],"alternate_names":["LECTIN COMPLEMENT ACTIVATION PATHWAY, DEFECT IN, 2"],"attribute_content":[]}
{"type":"Disease","keywords":[],"medgen_id":"C4310683","id":"36291","name":"Dyskinesia, seizures, and intellectual developmental disorder","alternate_symbols":["DYSEIDD"],"symbol":"NEDHELS","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0014952\"}","{\"db\":\"OMIM\",\"id\":\"617171\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"468620\"}","{\"db\":\"OMIM\",\"id\":\"617171\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"DYSEIDD\"}","{\"db\":\"OMIM\",\"id\":\"617171\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"alternate_names":[],"attribute_content":[]}
{"type":"Disease","keywords":[],"medgen_id":"C4014414","id":"18778","name":"Mental retardation, autosomal dominant 24","alternate_symbols":["IDDISBAS","MRD24"],"symbol":"VSVS","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0014357\"}","{\"db\":\"OMIM\",\"id\":\"615828\",\"type\":\"MIM\"}","{\"db\":\"OMIM\",\"id\":\"615828\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"INTELLECTUAL DEVELOPMENTAL DISORDER WITH IMPAIRED EXPRESSIVE SPEECH AND BEHAVIORAL ABNORMALITIES, WITH OR WITHOUT SEIZURES\"}","{\"db\":\"OMIM\",\"id\":\"602635.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"VULTO-VAN SILFHOUT-DE VRIES SYNDROME\"}","{\"db\":\"OMIM\",\"id\":\"602635.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"VULTO-VAN SILFHOUT-DE VRIES SYNDROME\"}","{\"db\":\"OMIM\",\"id\":\"602635.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"VULTO-VAN SILFHOUT-DE VRIES SYNDROME\"}","{\"db\":\"OMIM\",\"id\":\"602635.0004\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"VULTO-VAN SILFHOUT-DE VRIES SYNDROME\"}","{\"db\":\"OMIM\",\"id\":\"602635.0007\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"VULTO-VAN SILFHOUT-DE VRIES SYNDROME\"}","{\"db\":\"OMIM\",\"id\":\"602635.0008\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"VULTO-VAN SILFHOUT-DE VRIES SYNDROME\"}","{\"db\":\"OMIM\",\"id\":\"602635.0009\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"VULTO-VAN SILFHOUT-DE VRIES SYNDROME\"}","{\"db\":\"OMIM\",\"id\":\"602635.0010\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"VULTO-VAN SILFHOUT-DE VRIES SYNDROME\"}","{\"db\":\"OMIM\",\"id\":\"602635.0011\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"VULTO-VAN SILFHOUT-DE VRIES SYNDROME\"}","{\"db\":\"OMIM\",\"id\":\"602635.0012\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"VULTO-VAN SILFHOUT-DE VRIES SYNDROME\"}","{\"db\":\"OMIM\",\"id\":\"602635.0013\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"VULTO-VAN SILFHOUT-DE VRIES SYNDROME\"}","{\"db\":\"OMIM\",\"id\":\"615828\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"VULTO-VAN SILFHOUT-DE VRIES SYNDROME\"}","{\"db\":\"OMIM\",\"id\":\"615828\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"IDDISBAS\"}","{\"db\":\"OMIM\",\"id\":\"615828\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"MRD24\"}","{\"db\":\"OMIM\",\"id\":\"615828\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"alternate_names":["INTELLECTUAL DEVELOPMENTAL DISORDER WITH IMPAIRED EXPRESSIVE SPEECH AND BEHAVIORAL ABNORMALITIES, WITH OR WITHOUT SEIZURES","VULTO-VAN SILFHOUT-DE VRIES SYNDROME"],"attribute_content":[]}
{"type":"Disease","keywords":[],"medgen_id":"CN281158","id":"52485","name":"Liberfarb Syndrome","alternate_symbols":["SEMDLIBF"],"symbol":"LIBF","xrefs":["{\"db\":\"OMIM\",\"id\":\"618889\",\"type\":\"MIM\"}","{\"db\":\"OMIM\",\"id\":\"618889\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"SPONDYLOEPIMETAPHYSEAL DYSPLASIA, LIBERFARB TYPE\"}","{\"db\":\"OMIM\",\"id\":\"618889\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"SEMDLIBF\"}","{\"db\":\"OMIM\",\"id\":\"618889\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"alternate_names":["SPONDYLOEPIMETAPHYSEAL DYSPLASIA, LIBERFARB TYPE"],"attribute_content":[]}
